


Regioselective and Stereoselective Pd-Catalyzed Intramolecular Arylation of Furans: Access to Spirooxindoles and 5*H*-Furo[2,3-*c*]quinolin-4-ones

Jianchao Liu, Hui Peng, Yongjie Yang, Huanfeng Jiang, and Biaolin Yin*

Key Laboratory of Functional Molecular Engineering of Guangdong Province, School of Chemistry and Chemical Engineering, South China University of Technology, Guangzhou 510640, PR China

S Supporting Information


ABSTRACT: Herein, we report regio- and stereoselective intramolecular direct arylations of *N*-(2-bromophenyl)-2-furancarboxamides **1** to produce spirooxindoles **2** and 5*H*-furo[2,3-*c*]quinolin-4-ones **3** under different reaction conditions. Specifically, in the presence of Pd(PPh₃)₄ as a catalyst, PPh₃ as a ligand, and K₂CO₃ as a base, substrates **1** underwent intramolecular α -arylation, possibly via a Heck insertion pathway, to provide **2**, with the *Z*-isomer being favored. When the base was *t*-BuOLi and R¹ was an aryl group, the reaction favored *E*-**2**, possibly via an electrophilic palladation pathway. In contrast, in the presence of PdCl₂ as a catalyst, (o-OMePh)₃P as a ligand, and PivOH as an additive, substrates **1** underwent intramolecular β -arylation to provide **3**, possibly via a concerted metalation–deprotonation process.



INTRODUCTION

The synthesis of bi(hetero)aryl compounds, which have interesting bioactivities¹ and physical properties,² by means of direct arylation of five-membered heteroaromatic rings (such as furans, pyrroles, and thiophenes) is an important but challenging task in organic synthesis.³ Three major reaction pathways involving palladium catalysis have been proposed for this transformation (Scheme 1). One commonly proposed

Scheme 1. Major Pathways for Direct Arylation of Five-Membered Heteroaromatic Rings



pathway for reaction of π -electron-rich aromatic substrates is electrophilic aromatic substitution (S_EAr),⁴ whereby an ArPdX intermediate attacks at the most electronegative position of the heteroaromatic substrate (Scheme 1a). A Heck-type pathway involving β -H elimination⁵ (Scheme 1b) and a concerted metalation–deprotonation (CMD) process⁶ have also been


suggested (Scheme 1c). Recently, several groups have reported the regioselective direct arylation of five-membered heteroaromatic rings by means of elegant methods involving the use of different reaction conditions to alter the reaction pathway.⁷ For example, Sharp and co-workers^{5a} regioselectively arylated 3-furoate and 3-thiophenecarboxylate esters with aryl bromides and could change the reaction pathway by varying the palladium source and the solvent. Doucet^{7a} reported that the regioselectivity of the arylation of 2,5-disubstituted furans depended strongly on the base that was used.

Biomass derived α -substituted furans are readily available and are excellent, widely used building blocks for the construction of complex molecules.⁸ Direct arylation is an important tool for transforming α -substituted furans into other useful compounds (Scheme 2). Intermolecular arylation of α -monosubstituted furans generally occurs at the unsubstituted α -position.⁹ Intermolecular β -arylation of furans occurs only when both of the α -positions are substituted¹⁰ or when a 2-furancarboxamide is used as the substrate; the latter reaction involves chelation-assisted functionalization of the *ortho*-C–H bonds, directed by the amide group.¹¹ Intramolecular α -arylation of α -substituted furans usually leads to opening of the furan ring to form α,β -unsaturated carbonyl compounds.¹² Intramolecular β -arylation of α -furans has also been reported to afford annulated furans.¹³

Although numerous elegant methods for arylation of α -substituted furans have been reported and used to extend the synthetic applications of furans, tuning the regio- and

Received: July 25, 2016

Published: September 23, 2016

Scheme 2. α - and β -Arylation of α -Substituted Furans

stereoselectivities of furan arylation reactions by altering the reaction pathway by means of different reaction conditions has not yet been reported. As part of our ongoing work on furan dearomatization and palladium catalysis,¹⁴ in this study, we carried out regio- and stereoselective intramolecular arylation reactions of furans by using readily available *N*-(2-bromophenyl)-2-furancarboxamides **1** as the substrates (Scheme 2). These reactions afforded biologically interesting spirooxindoles **2**¹⁵ or 5*H*-furo[2,3-*c*]quinolin-4-ones **3**¹⁶ depending on the reaction conditions, and the reactions probably proceeded by three different pathways.

RESULTS AND DISCUSSION

We used 2-furancarboxamide **1a** as the substrate for optimization of the reaction conditions (Table 1). When **1a** was treated with Pd(PPh₃)₄ (5 mol %), PPh₃ (10 mol %) and K₂CO₃ (200 mol %) in 1,4-dioxane at 80 °C under nitrogen for 12 h, α -arylated spirooxindole **2a** was obtained in 93% yield as a 6:1 *Z/E* mixture (entry 1). The stereochemistry of **2a** was assigned by means of NOESY experiments (see the SI). The reaction did not occur in the absence of Pd(PPh₃)₄ (entry 2), and only a trace of **2a** was produced in the absence of a base (entry 3). Screening of a series of other bases revealed that the base clearly influenced the outcome of the reaction (entries 4–10). Among the weak bases, Na₂CO₃ gave **2a** in a yield (90%) and a *Z/E* ratio (5.8:1) that were comparable to those observed with K₂CO₃ (entry 4). The use of Cs₂CO₃ and DBU led to lower yields and *Z/E* ratios than K₂CO₃ (entries 5 and 6). Li₂CO₃ gave only a trace of **2a** (entry 7). Notably, strong bases (*t*-BuOLi, *t*-BuONa, and *t*-BuOK) gave **2a** in low yields but with stereoselectivities opposite to that observed with the weak

Table 1. Optimization of the α -Arylation of **1a**^a


entry	base	solvent	yield of 2a (%) ^b	<i>Z/E</i> ^b
1	K ₂ CO ₃	1,4-dioxane	93	6/1
2 ^c	K ₂ CO ₃	1,4-dioxane	NR	—
3	—	1,4-dioxane	trace	—
4	Na ₂ CO ₃	1,4-dioxane	90	5.8/1
5	Cs ₂ CO ₃	1,4-dioxane	48	5/1
6	DBU	1,4-dioxane	35	1/1
7	Li ₂ CO ₃	1,4-dioxane	trace	—
8	<i>t</i> -BuOLi	1,4-dioxane	53	1/2.7
9	<i>t</i> -BuONa	1,4-dioxane	45	1/2.5
10	<i>t</i> -BuOK	1,4-dioxane	52	1/1.5
11	K ₂ CO ₃	toluene	97	4.8/1
12	K ₂ CO ₃	DCE	98	12.5/1
13	K ₂ CO ₃	THF	80	2.6/1
14	K ₂ CO ₃	DMF	70	2.8/1
15	<i>t</i> -BuOLi	toluene	50	1/2
16	<i>t</i> -BuOLi	DCE	55	1/1.2
17	<i>t</i> -BuOLi	THF	60	1.3/1
18	<i>t</i> -BuOLi	DMF	37	1/1.2

^aReaction conditions, unless otherwise noted: **1a** (0.3 mmol), Pd(PPh₃)₄ (5 mol %), PPh₃ (10 mol %), base (200 mol %), solvent (3 mL), *T* = 80 °C, N₂ atmosphere, 12 h. NR = no reaction; ND = not detected. ^bYields and *Z/E* ratios were determined by ¹H NMR analysis with mesitylene as an internal standard. ^cThis reaction was carried out in the absence of Pd(PPh₃)₄.

bases; that is, the *E*-isomer was the major isomer (entries 8–10). Among these strong bases, *t*-BuOLi gave the highest yield (55%) and the lowest *Z/E* ratio (1/2.7) (entry 8). On the basis of these results, we used K₂CO₃ or *t*-BuOLi as the base to favor the synthesis of the *Z*- or *E*-isomer of **2a**, respectively. Solvent screening demonstrated that DCE was optimal when K₂CO₃ was the base (entry 12), whereas 1,4-dioxane was optimal for *t*-BuOLi (entry 8).

To investigate the scope of the reaction, we subjected various *N*-(2-bromophenyl)-2-furancarboxamides **1** with different R, R¹, and R² groups to the optimized reaction conditions (Table 1, entry 12) to synthesize a range of spirooxindoles **2**, with the *Z*-isomer as the major product (Table 2). The reaction had a broad substrate scope, and in most cases, expected spirooxindoles **2** were obtained in good to excellent yields (51–92%) and good *Z/E* selectivities (4:1–16:1). Specifically, R could be an H atom, an electron-donating group (Me, *t*-Bu, OMe), or an electron-withdrawing group (F). The R¹ substituent could be an alkyl group, a phenyl group (either unsubstituted or with an electron-donating or electron-withdrawing substituent), a thiophenyl group, or a naphthyl group. Notably, when R¹ was Me, the *Z/E* selectivities were lower (**2s–2u**) than those observed with other R¹ groups. The R² substituent could be a small alkyl group (Me, Et) or a slightly larger alkyl group (*i*-Pr), but when R² was H (**1v**), *O*-arylation occurred and the corresponding spirooxindole (**2v**) could not be isolated.


When **1a** (R¹ = Ph) and **1g–1h** (R¹ = *p*-Toly) were subjected to the reaction conditions listed in entry 8 of Table 1, these substrates were transformed to corresponding products **2** in moderate isolated yields, with the *E*-isomer being favored (*Z/E* = 1:1.5–1:2.7, Scheme 3). Notably, when the substrate was **1s**

Table 2. Scope of the α -Arylation Reaction^a

^aReaction conditions, unless otherwise noted: **1** (0.3 mmol), DCE (3 mL), $T = 80\text{ }^{\circ}\text{C}$, under N₂, 12 h. Yields are isolated yields. Z/E ratios were determined by ¹H NMR analysis. ND = not detected. ^b $T = 90\text{ }^{\circ}\text{C}$.

(R¹ = Me), the product **2s'** was formed still with the Z-isomer being favored.

In explanation of the stereoselectivity for the formation of **2** under the two different sets of reaction conditions, we propose the two paths shown in Scheme 4. The first step is oxidative addition of Pd(0) to **1** to produce palladium complex **4**. In the

Scheme 3. Synthesis of E-Isomers of **2a** and **2g–2h**^a

^aReaction conditions: **1** (0.3 mmol), 1,4-dioxane (3 mL), under N₂, 12 h. Yields are isolated yields. Z/E ratios were determined by ¹H NMR analysis.



presence of K₂CO₃ (path a), **4** undergoes a Heck-type α -arylation of the furan ring to produce alkyl palladium **5**. Alkyl palladium **5** isomerizes to allylic palladium **6** and then to alkyl palladium **7** and **7'**, which undergo β -H elimination to form **2**.¹⁷ The formation of **7** is favored, owing to the absence of an interaction between the olefinic proton and the phenyl group, and as a result, Z-**2** is the major. In contrast, when R¹ is an aryl group and *t*-BuOLi is used as the base (path b), deprotonation of the methylene carbon of **4** leads to carbanion **8**, which then undergoes a 1,7-lithium shift to form chelation complexes Z-**9** and E-**9**.¹⁸ Complexes **9** undergo electrophilic palladation to produce **10**, and subsequent reductive elimination affords **2**. Complex E-**9** is favored over Z-**9** owing to the lack of an interaction between the phenyl group and the lithium salt, and as a result, E-**2** is the major product. When R¹ is a methyl group, due to low acidity of the proton of the methylene carbon, the deprotonation of **4s** by *t*-BuOLi to **8s** is suppressed, thus **2s'** is formed through Heck-type insertion still with the Z-isomer as the major product.

Having investigated dearomatizing α -arylation of **1** to form spirooxindoles **2**, we next searched for suitable conditions to achieve intramolecular β -arylation to form β -arylated products **3** by suppressing α -arylation and enhancing the acidity of the β -H. Addition of a protonic acid, such as pivalic acid (PivOH), is known to increase the acidity of C–H protons during transformations involving C–H functionalization.¹⁹ Thus, we set out to optimize the reaction conditions for the formation of **3** from substrate **1a** by using PivOH as an additive (Table 3). With Pd(OAc)₂ as the catalyst, PCy₃·HBF₄ as the ligand, and Cs₂CO₃ as the base, reaction of **1a** at 100 °C in toluene provided **3a** and **2a** in 58% and 30% yields, respectively (entry 1). In the absence of PivOH, **2a** was the only product (85% yield, entry 2). Solvent screening demonstrated that toluene was optimal for the formation of **3a** (entries 3–8). Various ligands were then examined, and the ligand was found to strongly influence the reaction outcome (entries 9–13). The electron-rich phenyl phosphine ligand (*o*-OCH₃Ph)₃P (L₃) gave the highest yield of **3a** (78%, entry 10). Finally, different palladium sources were evaluated (entries 14–17), and PdCl₂ was determined to be the best, giving **3a** in 86% yield (entry 16).

We subjected various substrates **1** with different R, R¹, and R² groups to the optimized conditions (Table 3, entry 16) to evaluate the generality of the β -arylation reaction (Table 4). The substrate scope was broad, and most of the substrates **1** could be transformed into 5H-furo[2,3-*c*]quinolin-4-ones **3** in good yields (70–82%). Specifically, R could be a H atom, an electron-donating group (Me, *t*-Bu, OMe), or an electron-withdrawing group (F). The R¹ substituent could be an alkyl group, a phenyl group (either unsubstituted or with an electron-donating or electron-withdrawing substituent), or a thiophenyl group. The R² substituent could be a small alkyl group (Me, Et), but when R² was H (**1p**) or a larger alkyl group (*i*-Pr, **1s**), the expected products (**3p** and **3s**, respectively) were not observed.

A mechanism for the formation of **3** is proposed in Scheme 5. Oxidative addition of Pd(0) to **1** produces palladium complex **4**. Nucleophilic attack of **4** by pivalate anion produces ArPd(OPiv) complex **10**, which forms a CMD transition state (**11**) via activation of the β -C–H bond of the furan ring. After a release of PivOH, **11** is transformed into biaryl palladium species **12**, which is subsequently converted to complex **13**.

Scheme 4. Proposed Mechanisms for Formation of 2 under Different Reaction Conditions



Table 3. Optimization of the Reaction Conditions for the β -Arylation of 1a^a

entry	[Pd]	L	solvent	yield of 3a (%) ^b	yield of 2a (%) ^b
1	Pd(OAc) ₂	L ₁	toluene	58	30
2 ^c	Pd(OAc) ₂	L ₁	toluene	ND	85
3	Pd(OAc) ₂	L ₁	DCE	55	32
4	Pd(OAc) ₂	L ₁	CH ₃ CN	38	35
5	Pd(OAc) ₂	L ₁	THF	40	42
6	Pd(OAc) ₂	L ₁	1,4-dioxane	42	45
7	Pd(OAc) ₂	L ₁	DMA	45	40
8	Pd(OAc) ₂	L ₁	DMSO	30	35
9	Pd(OAc) ₂	L ₂	toluene	ND	65
10	Pd(OAc) ₂	L ₃	toluene	78	15
11	Pd(OAc) ₂	PCy ₃	toluene	60	24
12	Pd(OAc) ₂	PPh ₃	toluene	46	40
13	Pd(OAc) ₂	Binap	toluene	50	31
14	Pd(PPh ₃) ₄	L ₃	toluene	72	23
15	Pd ₂ (dba) ₃	L ₃	toluene	76	15
16	PdCl ₂	L ₃	toluene	86	8
17	PdBr ₂	L ₃	toluene	80	12

^aReaction conditions, unless otherwise noted: 1 (0.3 mmol), [Pd] (5 mol %), L (10 mol %), Cs₂CO₃ (150 mol %), PivOH (30 mol %), solvent (3 mL), under N₂, 100 °C, 12 h. L₁ = PCy₃·HBF₄, L₂ = (*o*-CH₃Ph)₃P, L₃ = (*o*-OCH₃Ph)₃P. ND = not detected. ^bYields were determined by ¹H NMR analysis with mesitylene as an internal standard. ^cNo PivOH was used in this reaction.

Complex 13 then undergoes reductive elimination to give 3 and regenerate Pd(0).


When *N*-benzyl-2-furancarboxamide 1ab was subjected to the optimized reaction conditions for the α - and β -arylations, the substrate was transformed into [5,6]spirooxindole 2w (60% yield, 12:1 Z/E mixture) and seven-membered lactam 3t (56% yield), respectively (Scheme 6).

Table 4. Substrate Scope of the β -Arylation^a

^aReaction conditions: 1 (0.3 mmol), toluene (3 mL), under N₂, 12 h. Yields are isolated yields.

CONCLUSION

In summary, we achieved regioselective Pd-catalyzed intramolecular direct arylation of the furan rings of *N*-(2-bromophenyl)-2-furancarboxamides using different reaction conditions to efficiently synthesize biologically interesting spirooxindoles and 5*H*-furo[2,3-*c*]quinolin-4-ones. Interestingly, when R¹ of 1 was an aryl group, Z and E favored spirooxindoles can be formed using K₂CO₃ and *t*-BuOLi as the base, respectively. We propose three possible pathways for these transformations—namely, Heck insertion, electrophilic palladation, and CMD—indicating the versatility of this Pd-catalyzed direct arylation for the transformation of furans. In particular, the dearomatizing intramolecular α -arylation that occurred without opening of the furan ring is of great

Scheme 5. Proposed Mechanism for the Formation of **3**

significance for extending the synthetic applications of furan derivatives.

EXPERIMENTAL SECTION

General Information. IR spectra were recorded with FT-IR as a thin film or using KBr pellets and are expressed in cm^{-1} . ^1H (400 MHz) and ^{13}C (100 MHz) NMR spectra were recorded using CDCl_3 as a solvent. Chemical shifts are reported in ppm downfield to tetramethylsilane. Coupling constants are reported and expressed in Hz; splitting patterns are designated as s (singlet), d (doublet), t (triplet), q (quartet), m (multiplet), dd (double doublet), dt (double triplet), dq (double quartet), br (broad). Mass spectra were obtained from high resolution ESI mass spectrometer. All reactions were carried out using freshly distilled and dry solvents. Column chromatography was performed over silica gel (100–200 Mesh) using petroleum ether and ethyl acetate as the eluent. The structures of **S1**, **S2**, **S3**, **S4**, **S5**, **S6**, **S7** are shown in the [Supporting Information](#).

General Procedure for the Preparation of 1. Method A. Synthesis of **S2**: To a solution of 5-substituted-benzoylfuran-2-carboxylate (**S1**) (10 mmol) in MeOH (20 mL) was added NaBH_4 (418.0 mg, 11 mmol) in portions at 0 °C. After stirring at the same temperature for 1 h, H_2O (30 mL) was added to quench the reaction. Removal of MeOH under reduced pressure provided the aqueous layer which was extracted with EtOAc (10 mL \times 3). The combined organic layers were washed with saturated brine, dried over Na_2SO_4 , concentrated under reduced pressure, providing a colorless liquid.

To the solution of the above-made liquid in CH_2Cl_2 (40 mL) was added CF_3COOH (2.5 g, 22 mmol) then Et_3SiH (2.55 g, 22 mmol) in portions at 0 °C. The reaction was stirred for 30 min, then H_2O (20 mL) was added to quench the reaction. The resulting mixture was extracted with CH_2Cl_2 (10 mL \times 3), and the combined organic layers were washed with saturated brine, dried over sodium sulfate, concentrated under reduced pressure. The residue was purified by

flash chromatography on a silica gel (using petroleum ether/ethyl acetate =30:1 as the eluent) to give product **S2** (**S2a**–**S2g**).

Methyl 5-benzylfuran-2-carboxylate (S2a). Colorless oil (1.85 g, 86% over 2 steps); IR (film) 2951, 1726, 1496, 1308, 1019, 797 cm^{-1} ; ^1H NMR (400 MHz, CDCl_3) δ 7.38–7.31 (m, 2H), 7.30–7.27 (m, 3H), 7.12 (d, J = 3.3 Hz, 1H), 6.09 (d, J = 3.3 Hz, 1H), 4.06 (s, 2H), 3.89 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 159.6, 159.2, 143.4, 136.6, 128.8, 128.6, 126.9, 119.2, 108.9, 51.7, 34.7; HRMS (ESI) m/z calcd for $\text{C}_{13}\text{H}_{12}\text{NaO}_3$ [$M + \text{Na}$] $^+$: 239.0679, found 239.0689.

Methyl 5-(4-methylbenzyl)furan-2-carboxylate (S2b). Colorless oil (2.07 g, 90% over 2 steps); IR (film) 2951, 1726, 1595, 1436, 1201, 1020, 927 cm^{-1} ; ^1H NMR (400 MHz, CDCl_3) δ 7.15–7.09 (m, 4H), 7.07 (d, J = 3.4 Hz, 1H), 6.04 (d, J = 3.4 Hz, 1H), 3.97 (s, 2H), 3.84 (s, 3H), 2.31 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 160.0, 159.2, 143.3, 136.4, 133.6, 129.3, 128.7, 119.2, 108.7, 51.7, 34.3, 21.0; HRMS (ESI) m/z calcd for $\text{C}_{14}\text{H}_{14}\text{NaO}_3$ [$M + \text{Na}$] $^+$: 253.0835, found 253.0845.


Methyl 5-(4-chlorobenzyl)furan-2-carboxylate (S2c). Colorless oil (2.12 g, 85% over 2 steps); IR (film) 2952, 1725, 1592, 1435, 1201, 1016, 927 cm^{-1} ; ^1H NMR (400 MHz, CDCl_3) δ 7.28 (d, J = 8.4 Hz, 2H), 7.17 (d, J = 8.4 Hz, 2H), 7.10 (d, J = 3.4 Hz, 1H), 6.08 (d, J = 3.4 Hz, 1H), 4.00 (s, 2H), 3.87 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 159.3, 158.9, 143.5, 135.1, 132.8, 130.1, 128.8, 119.3, 109.0, 51.9, 34.0; HRMS (ESI) m/z calcd for $\text{C}_{13}\text{H}_{11}\text{ClNaO}_3$ [$M + \text{Na}$] $^+$: 273.0298, found 273.0298.

Methyl 5-(4-methoxybenzyl)furan-2-carboxylate (S2d). Colorless oil (2.16 g, 88% over 2 steps); IR (film) 2951, 1725, 1604, 1437, 1249, 1027 cm^{-1} ; ^1H NMR (400 MHz, CDCl_3) δ 7.15 (d, J = 8.6 Hz, 2H), 7.08 (d, J = 3.4 Hz, 1H), 6.84 (d, J = 8.6 Hz, 2H), 6.04 (d, J = 3.4 Hz, 1H), 3.97 (s, 2H), 3.86 (s, 3H), 3.79 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 160.1, 159.2, 158.5, 143.3, 129.8, 128.7, 119.2, 114.1, 108.6, 55.2, 51.7, 33.9; HRMS (ESI) m/z calcd for $\text{C}_{14}\text{H}_{14}\text{NaO}_4$ [$M + \text{Na}$] $^+$: 269.0784, found 269.0793.

Ethyl 5-(2-methylbenzyl)furan-2-carboxylate (S2e). Colorless oil (2.09 g, using ethyl-2-furoate as the start material, 86% over 2 steps); IR (film) 2980, 1720, 1456, 1206, 965 cm^{-1} ; ^1H NMR (400 MHz, CDCl_3) δ 7.22–7.17 (m, 4H), 7.09 (d, J = 3.2 Hz, 1H), 5.94 (d, J = 3.2 Hz, 1H), 4.37 (q, J = 7.1 Hz, 2H), 4.05 (s, 2H), 2.31 (s, 3H), 1.39 (t, J = 7.1 Hz, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 159.2, 158.9, 143.6, 136.5, 134.9, 130.4, 129.7, 127.2, 126.2, 119.0, 108.7, 60.7, 32.6, 19.3, 14.3; HRMS (ESI) m/z calcd for $\text{C}_{15}\text{H}_{16}\text{NaO}_3$ [$M + \text{Na}$] $^+$: 267.0992, found 267.1000.

Methyl 5-(thiophen-2-ylmethyl)furan-2-carboxylate (S2f). Colorless oil (1.89 g, 85% over 2 steps); IR (film) 2952, 1725, 1434, 1203, 1022, 927 cm^{-1} ; ^1H NMR (400 MHz, CDCl_3) δ 7.17 (d, J = 5.1, 1H), 7.09 (d, J = 3.4 Hz, 1H), 6.93 (dd, J = 5.1, 3.5 Hz, 1H), 6.89 (d, J = 3.4, 1H), 6.17 (d, J = 3.4 Hz, 1H), 4.22 (s, 2H), 3.85 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 159.1, 158.4, 143.5, 138.4, 127.0, 126.2, 124.5, 119.2, 108.9, 51.7, 28.9; HRMS (ESI) m/z calcd for $\text{C}_{11}\text{H}_{10}\text{O}_3\text{NaS}$ [$M + \text{Na}$] $^+$: 245.0243, found 245.0251.

Methyl 5-(naphthalen-2-ylmethyl)furan-2-carboxylate (S2g). Colorless solid (2.39 g, 90% over 2 steps), mp 68.6–69.5 °C; IR (film) 2951, 1724, 1595, 1434, 1203, 809 cm^{-1} ; ^1H NMR (400 MHz, CDCl_3) δ 7.82–7.72 (m, 3H), 7.67 (s, 1H), 7.49–7.40 (m, 2H), 7.34 (dd, J = 8.4, 1.1 Hz, 1H), 7.09 (d, J = 3.4 Hz, 1H), 6.07 (d, J = 3.3 Hz, 1H), 4.17 (s, 2H), 3.85 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 159.5, 159.2, 143.5, 134.1, 133.5, 132.4, 128.4, 127.6, 127.6, 127.4, 127.0, 126.2, 125.8, 119.3, 109.1, 51.8, 34.9; HRMS (ESI) m/z calcd for $\text{C}_{17}\text{H}_{14}\text{NaO}_3$ [$M + \text{Na}$] $^+$: 289.0835, found 289.0838.

Scheme 6. Synthesis of **2w** and **3t**

Synthesis of **1**: To the solution of **S2** (5 mmol) in THF (5 mL) was added aqueous NaOH (2 N, 10 mL) slowly. The reaction was stirred at room temperature until the disappearance of **S2** according to the TLC. The organic solvent was removed under reduced pressure, then aqueous HCl (2 N) was added slowly to acidify the aqueous solution (pH = 2). The resulting mixture was extracted with EtOAc (10 mL × 3), the combined organic layers were washed with saturated brine, dried over Na₂SO₄, concentrated under reduced pressure, providing a white solid (**S3**).

To a round-bottom 50 mL flask equipped with a condenser pipe and a drying tube was added the above-obtained solid (**S3**) then SOCl₂ (20 mL). The mixture was heated to reflux for 3 h. The excessive SOCl₂ was removed under reduced pressure. Dry CH₂Cl₂ (5 mL) was added to the residue to form a clear solution. The solution was slowly added to a mixture of 2-bromoaniline (**S4**, 5.5 mmol), triethylamine (1.01 g, 10 mmol) and CH₂Cl₂ (5 mL) at 0 °C. After the addition, the solution was stirring at room temperature for 30 min, and then H₂O (30 mL) was added. The resulting mixture was extracted with EtOAc (10 mL × 3), the combined organic layers were washed with brine, dried over Na₂SO₄, concentrated under reduced pressure. The residue was purified by flash chromatography on a silica gel (using PE/EtOAc = 12:1 as the eluent) to give product **1** (**1a–q**, **1u–y**, **1ab**).

5-Benzyl-N-(2-bromophenyl)-N-ethylfuran-2-carboxamide (1a). Colorless oil (1.21 g, 63% over 4 steps); IR (film) 2977, 2932, 1720, 1640, 1211, 969 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 7.62 (dd, *J* = 7.9, 1.2 Hz, 1H), 7.35–7.30 (m, 1H), 7.29–7.27 (m, 2H), 7.26–7.24 (m, 1H), 7.24–7.22 (m, 1H), 7.22–7.18 (m, 1H), 7.07 (d, *J* = 7.1 Hz, 2H), 6.05 (br, 1H), 5.84 (br, 1H), 4.28–4.16 (m, 1H), 3.78 (s, 2H), 3.55–3.45 (m, 1H), 1.23 (t, *J* = 7.2 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 158.7, 157.2, 146.4, 141.4, 137.0, 133.7, 131.1, 129.5, 128.7, 128.5, 128.2, 126.6, 124.2, 117.4, 108.1, 44.4, 34.4, 12.7; HRMS (ESI) *m/z* calcd for C₂₀H₁₉BrNO₂ [M + H]⁺: 384.0594, found 384.0608.

5-Benzyl-N-(2-bromo-4-methylphenyl)-N-ethylfuran-2-carboxamide (1b). Colorless oil (1.31 g, 66% over 4 steps); IR (film) 2975, 1722, 1641, 1522, 1448, 1210, 969 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 7.42 (s, 1H), 7.29–7.17 (m, 3H), 7.12–7.03 (m, 4H), 5.93 (br, 1H), 5.81 (br, 1H), 4.23–4.12 (m, 1H), 3.80 (s, 2H), 3.51–3.37 (m, 1H), 2.34 (s, 3H), 1.19 (t, *J* = 7.2 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 158.8, 157.1, 146.4, 139.9, 138.6, 137.1, 134.1, 130.7, 128.9, 128.7, 128.5, 126.6, 123.8, 117.2, 108.1, 44.4, 34.5, 20.9, 12.6; HRMS (ESI) *m/z* calcd for C₂₁H₂₁BrNO₂ [M + H]⁺: 398.0750, found 398.0757.

5-Benzyl-N-(2-bromo-4-tert-butylphenyl)-N-ethylfuran-2-carboxamide (1c). Colorless oil (1.32 g, 60% over 4 steps); IR (film) 2926, 1743, 1688, 1643, 1464, 1212, 1024, 967 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 7.63 (s, 1H), 7.34 (d, *J* = 8.2 Hz, 1H), 7.29–7.25 (m, 2H), 7.24–7.13 (m, 2H), 7.08 (d, *J* = 7.2 Hz, 2H), 5.93 (br, 1H), 5.78 (br, 1H), 4.25–4.15 (m, 1H), 3.76 (s, 2H), 3.52–3.42 (m, 1H), 1.31 (s, 9H), 1.22 (t, *J* = 7.0 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 158.7, 157.2, 153.4, 146.3, 138.6, 137.1, 130.7, 130.5, 128.7, 128.5, 126.6, 125.3, 123.8, 117.2, 108.1, 44.4, 34.8, 34.4, 31.2, 12.7; HRMS (ESI) *m/z* calcd for C₂₄H₂₆BrNNO₂ [M + Na]⁺: 462.1039, found 462.1039.

5-Benzyl-N-(2-bromo-4-methoxyphenyl)-N-ethylfuran-2-carboxamide (1d). Colorless oil, (1.34 g, 65% over 4 steps); IR (film) 2934, 1721, 1640, 1216, 970 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 7.49–7.43 (m, 1H), 7.29–7.23 (m, 2H), 7.22–7.17 (m, 1H), 7.06 (d, *J* = 7.2 Hz, 2H), 6.78–6.72 (m, 2H), 6.09 (br, 1H), 5.85 (br, 1H), 4.21–4.10 (m, 1H), 3.79 (s, 2H), 3.74 (s, 3H), 3.58–3.45 (m, 1H), 1.22 (t, *J* = 7.2 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 159.5, 158.7, 157.2, 146.3, 142.0, 137.1, 133.8, 128.7, 128.5, 126.6, 117.4, 116.6, 115.4, 114.5, 108.2, 55.7, 44.6, 34.5, 12.7; HRMS (ESI) *m/z* calcd for C₂₁H₂₁BrNO₃ [M + H]⁺: 414.0699, found 414.0705.

5-Benzyl-N-(2-bromo-4-fluorophenyl)-N-ethylfuran-2-carboxamide (1e). Colorless oil (1.1 g, 55% over 4 steps); IR (film) 2930, 1719, 1639, 1451, 1264, 967 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 7.28–7.21 (m, 4H), 7.18–7.13 (m, 1H), 7.02 (d, *J* = 6.7 Hz, 2H), 6.97 (t, *J* = 8.0 Hz, 1H), 6.28 (br, 1H), 5.91 (br, 1H), 4.22–4.11 (m, 1H), 3.75 (s, 2H), 3.51–3.40 (m, 1H), 1.19 (t, *J* = 7.1 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 161.4 (d, *J*_{C–F} = 253.4 Hz), 158.7, 157.2, 146.5,

137.6 (d, *J*_{C–F} = 4.0 Hz), 136.9, 131.7 (d, *J*_{C–F} = 9.1 Hz), 128.6, 128.5, 126.7, 124.6 (d, *J*_{C–F} = 10.2 Hz), 120.7 (d, *J*_{C–F} = 25.2 Hz), 117.8, 115.2 (d, *J*_{C–F} = 22.2 Hz), 108.3, 44.5, 34.5, 12.6; HRMS (ESI) *m/z* calcd for C₂₀H₁₈BrFNO₂ [M + H]⁺: 402.0499, found 402.0511.

N-(2-Bromophenyl)-N-ethyl-5-(4-methylbenzyl)furan-2-carboxamide (1f). Colorless oil (1.23 g, 62% over 4 steps); IR (film) 2976, 1641, 1480, 1211, 1023, 969 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 7.63 (dd, *J* = 7.9, 1.3 Hz, 1H), 7.35–7.30 (m, 1H), 7.26–7.18 (m, 2H), 7.08 (d, *J* = 7.9 Hz, 2H), 6.97 (d, *J* = 7.8 Hz, 2H), 6.03 (d, *J* = 2.2 Hz, 1H), 5.82 (d, *J* = 2.2 Hz, 1H), 4.26–4.18 (m, 1H), 3.74 (s, 2H), 3.56–3.47 (m, 1H), 2.33 (s, 3H), 1.24 (t, *J* = 7.2 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 158.8, 157.6, 146.3, 141.4, 136.1, 133.9, 133.7, 131.1, 129.4, 129.1, 128.6, 128.2, 124.2, 117.4, 107.9, 44.4, 34.0, 21.0, 12.7; HRMS (ESI) *m/z* calcd for C₂₁H₂₁BrNO₂ [M + H]⁺: 398.0750, found 398.0762.

N-(2-Bromo-4-methylphenyl)-N-ethyl-5-(4-methylbenzyl)furan-2-carboxamide (1g). Colorless oil (1.33 g, 65% over 4 steps); IR (film) 2975, 1642, 1446, 1210, 969 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 7.43 (s, 1H), 7.10 (d, *J* = 8.8 Hz, 2H), 7.06 (d, *J* = 7.8 Hz, 2H), 6.96 (d, *J* = 7.8 Hz, 2H), 5.91 (br, 1H), 5.78 (br, 1H), 4.25–4.12 (m, 1H), 3.76 (s, 2H), 3.50–3.41 (m, 1H), 2.35 (s, 3H), 2.31 (s, 3H), 1.20 (t, *J* = 7.1 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 158.9, 157.5, 146.2, 139.9, 138.7, 136.1, 134.1, 134.0, 130.7, 129.1, 128.9, 128.6, 123.8, 117.2, 107.9, 44.4, 34.1, 21.0, 20.8, 12.6; HRMS (ESI) *m/z* calcd for C₂₂H₂₃BrNO₂ [M + H]⁺: 412.0907, found 412.0920.

N-(2-Bromo-4-methoxyphenyl)-N-ethyl-5-(4-methylbenzyl)furan-2-carboxamide (1h). Colorless oil (1.45 g, 68% over 4 steps); IR (film) 2931, 1642, 1473, 1216, 970 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 7.49 (d, *J* = 9.6 Hz, 1H), 7.08 (d, *J* = 7.8 Hz, 2H), 6.98 (d, *J* = 7.8 Hz, 2H), 6.84–6.76 (m, 2H), 6.10 (br, 1H), 5.85 (br, 1H), 4.21–4.12 (m, 1H), 3.77 (s, 2H), 3.77 (s, 3H), 3.58–3.49 (m, 1H), 2.33 (s, 3H), 1.25 (t, *J* = 7.2 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 159.5, 158.7, 157.6, 146.2, 142.1, 136.1, 134.0, 133.8, 129.2, 128.6, 117.4, 116.6, 115.4, 114.5, 107.9, 55.7, 44.6, 34.1, 21.0, 12.7; HRMS (ESI) *m/z* calcd for C₂₂H₂₃BrNO₃ [M + H]⁺: 428.0856, found 428.0869.

N-(2-Bromo-5-methylphenyl)-N-ethyl-5-(4-methylbenzyl)furan-2-carboxamide (1i). Colorless oil (1.34 g, 65% over 4 steps); IR (film) 2976, 1643, 1472, 1211, 969 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 7.47 (d, *J* = 8.1 Hz, 1H), 7.08–7.02 (m, 3H), 7.00 (d, *J* = 8.2 Hz, 1H), 6.95 (d, *J* = 7.8 Hz, 2H), 5.97 (br, 1H), 5.80 (br, 1H), 4.20–4.10 (m, 1H), 3.74 (s, 2H), 3.54–3.44 (m, 1H), 2.30 (s, 3H), 2.28 (s, 3H), 1.21 (t, *J* = 7.2 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 158.7, 157.5, 146.3, 141.1, 138.5, 136.1, 134.0, 133.2, 131.6, 130.3, 129.1, 128.6, 120.6, 117.3, 107.9, 44.5, 34.1, 21.0, 20.8, 12.7; HRMS (ESI) *m/z* calcd for C₂₂H₂₂BrNNO₂ [M + Na]⁺: 434.0726, found 434.0728.

N-(2-Bromophenyl)-5-(4-chlorobenzyl)-N-ethylfuran-2-carboxamide (1j). Colorless oil (1.25 g, 60% over 4 steps); IR (film) 2976, 1743, 1641, 1482, 1210, 968 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 7.58 (d, *J* = 7.9 Hz, 1H), 7.31–7.26 (m, 1H), 7.25–7.14 (m, 4H), 6.97 (d, *J* = 8.0 Hz, 2H), 6.05 (br, 1H), 5.84 (br, 1H), 4.28–4.09 (m, 1H), 3.73 (s, 2H), 3.55–3.42 (m, 1H), 1.21 (t, *J* = 7.1 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 158.7, 156.4, 146.6, 141.3, 135.5, 133.7, 132.5, 131.1, 130.0, 129.5, 128.6, 128.2, 124.1, 117.3, 108.3, 44.5, 33.8, 12.6; HRMS (ESI) *m/z* calcd for C₂₀H₁₈BrClNO₂ [M + H]⁺: 418.0204, found 418.0212.

N-(2-Bromo-4-methylphenyl)-5-(4-chlorobenzyl)-N-ethylfuran-2-carboxamide (1k). Colorless oil (1.24 g, 58% over 4 steps); IR (film) 2927, 1643, 1495, 1272, 1210, 966 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 7.41 (s, 1H), 7.22 (d, *J* = 8.2 Hz, 2H), 7.08 (br, 2H), 6.99 (d, *J* = 8.2 Hz, 2H), 5.95 (br, 1H), 5.83 (br, 1H), 4.22–4.10 (m, 1H), 3.77 (s, 2H), 3.52–3.37 (m, 1H), 2.35 (s, 3H), 1.19 (t, *J* = 7.1 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 158.8, 156.3, 146.6, 139.9, 138.6, 135.6, 134.1, 132.4, 130.6, 130.0, 128.9, 128.6, 123.7, 117.1, 108.3, 44.5, 33.8, 20.8, 12.6; HRMS (ESI) *m/z* calcd for C₂₁H₂₀BrClNO₂ [M + H]⁺: 432.0360, found 432.0373.

N-(2-Bromo-4-methylphenyl)-N-ethyl-5-(4-methoxybenzyl)furan-2-carboxamide (1l). Colorless oil (1.32 g, 62% over 4 steps); IR (film) 2931, 1641, 1397, 969 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 7.46 (s, 1H), 7.12 (br, 2H), 7.01 (d, *J* = 8.5 Hz, 2H), 6.81 (d, *J* = 8.5

H₂, 2H), 5.93 (br, 1H), 5.80 (br, 1H), 4.25–4.15 (m, 1H), 3.80 (s, 3H), 3.76 (s, 2H), 3.52–3.43 (m, 1H), 2.37 (s, 3H), 1.22 (t, *J* = 7.2 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 158.9, 158.4, 157.7, 146.3, 139.9, 138.6, 134.1, 130.7, 129.7, 129.2, 128.9, 123.8, 117.2, 113.9, 107.9, 55.2, 44.4, 33.6, 20.8, 12.6; HRMS (ESI) *m/z* calcd for C₂₂H₂₃BrNO₃ [M + H]⁺: 428.0856, found 428.0862.

***N*-(2-Bromophenyl)-*N*-ethyl-5-(2-methylbenzyl)furan-2-carboxamide (1m).** Colorless oil (1.29 g, 65% over 4 steps); IR (film) 2975, 1642, 1474, 1211, 969 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 7.63 (d, *J* = 7.9 Hz, 1H), 7.34–7.30 (m, 1H), 7.26–7.20 (m, 2H), 7.15–7.11 (m, 3H), 6.98 (d, *J* = 6.6 Hz, 1H), 5.98 (br, 1H), 5.71 (br, 1H), 4.27–4.17 (m, 1H), 3.78 (s, 2H), 3.58–3.48 (m, 1H), 2.19 (s, 3H), 1.24 (t, *J* = 7.1 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 158.8, 156.9, 146.2, 141.4, 136.4, 135.2, 133.7, 131.1, 130.3, 129.7, 129.5, 128.2, 126.9, 126.1, 124.2, 117.4, 108.1, 44.4, 32.2, 19.4, 12.7; HRMS (ESI) *m/z* calcd for C₂₁H₂₁BrNO₂ [M + H]⁺: 398.0750, found 398.0757.

***N*-(2-Bromophenyl)-5-(2-chlorobenzyl)-*N*-ethylfuran-2-carboxamide (1n).** Colorless oil (1.27 g, 61% over 4 steps); IR (film) 2929, 1701, 1472, 1270, 1025, 967 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 7.60 (dd, *J* = 7.9, 1.0 Hz, 1H), 7.35–7.28 (m, 2H), 7.25–7.15 (m, 4H), 7.04–7.01 (m, 1H), 6.08 (br, 1H), 5.87 (br, 1H), 4.26–4.16 (m, 1H), 3.90 (s, 2H), 3.56–3.46 (m, 1H), 1.23 (t, *J* = 7.2 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 158.7, 155.4, 146.5, 141.4, 134.9, 133.9, 133.7, 131.1, 130.8, 129.4, 128.2, 128.1, 126.9, 126.9, 124.1, 117.4, 108.7, 44.4, 31.9, 12.6; HRMS (ESI) *m/z* calcd for C₂₀H₁₇BrClNNO₂ [M + Na]⁺: 440.0023, found 440.0024.

***N*-(2-Bromo-4-methylphenyl)-*N*-ethyl-5-(thiophen-2-ylmethyl)furan-2-carboxamide (1o).** Colorless oil (1.1 g, 55% over 4 steps); IR (film) 2927, 1743, 1642, 1391, 1271, 968 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 7.47 (s, 1H), 7.16 (dd, *J* = 5.1, 0.7 Hz, 1H), 7.13 (s, 2H), 6.94–6.91 (m, 1H), 6.76 (s, 1H), 5.92 (br, 2H), 4.29–4.11 (m, 1H), 4.03 (s, 2H), 3.54–3.45 (m, 1H), 2.38 (s, 3H), 1.22 (t, *J* = 7.2 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 158.8, 156.0, 146.4, 140.0, 138.9, 138.6, 134.1, 130.7, 129.1, 126.8, 125.9, 124.2, 123.7, 117.1, 108.1, 44.4, 28.7, 20.9, 12.6; HRMS (ESI) *m/z* calcd for C₁₉H₁₈BrNNO₂S [M + Na]⁺: 426.0134, found 426.0146.

***N*-(2-Bromophenyl)-*N*-ethyl-5-(*n*-phthalen-2-ylmethyl)furan-2-carboxamide (1p).** Colorless oil (1.15 g, 53% over 4 steps); IR (film) 2975, 1744, 1688, 1473, 1212, 966 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 7.81–7.70 (m, 3H), 7.49–7.42 (m, 4H), 7.17 (t, *J* = 9.1 Hz, 3H), 7.04–7.01 (m, 1H), 6.11 (br, 1H), 5.87 (br, 1H), 4.22–4.12 (m, 1H), 3.91 (s, 2H), 3.54–3.44 (m, 1H), 1.20 (t, *J* = 7.2 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 158.8, 157.0, 146.6, 141.3, 134.5, 133.6, 133.5, 132.3, 130.9, 129.3, 128.1, 127.6, 127.6, 127.2, 127.1, 126.1, 125.6, 124.1, 117.5, 108.4, 99.9, 44.5, 34.7, 12.7; HRMS (ESI) *m/z* calcd for C₂₄H₂₁BrNO₂ [M + H]⁺: 434.0750, found 434.0761.

***N*-(2-Bromo-4-methylphenyl)-*N*-ethyl-5-(*n*-aphthalen-2-ylmethyl)furan-2-carboxamide (1q).** Colorless oil (1.20 g, 54% over 4 steps); IR (film) 2974, 1641, 1448, 1211, 967 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 7.82–7.69 (m, 3H), 7.54–7.40 (m, 3H), 7.32 (s, 1H), 7.19 (d, *J* = 8.3 Hz, 1H), 7.07 (d, *J* = 7.9 Hz, 1H), 7.02 (d, *J* = 8.0 Hz, 1H), 5.99 (br, 1H), 5.86 (br, 1H), 4.22–4.12 (m, 1H), 3.97 (s, 2H), 3.49–3.40 (m, 1H), 2.22 (s, 3H), 1.19 (t, *J* = 7.1 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 156.9, 146.5, 139.9, 138.6, 134.6, 134.0, 133.5, 132.3, 130.6, 128.9, 128.1, 127.6, 127.6, 127.1, 127.1, 126.1, 125.6, 123.7, 117.2, 108.4, 99.9, 44.4, 34.6, 20.7, 12.6; HRMS (ESI) *m/z* calcd for C₂₅H₂₃BrNO₂ [M + H]⁺: 448.0907, found 448.0914.

5-Benzyl-*N*-(2-bromo-5-methylphenyl)-*N*-ethylfuran-2-carboxamide (1u). Colorless oil (1.24 g, 62% over 4 steps); IR (film) 2964, 1642, 1452, 1269, 970 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 7.48 (d, *J* = 8.1 Hz, 1H), 7.29–7.25 (m, 2H), 7.24–7.19 (m, 1H), 7.08 (d, *J* = 7.1 Hz, 2H), 7.06 (s, 1H), 7.02 (d, *J* = 8.2 Hz, 1H), 6.01 (br, 1H), 5.84 (br, 1H), 4.22–4.12 (m, 1H), 3.81 (s, 2H), 3.57–3.47 (m, 1H), 2.30 (s, 3H), 1.24 (t, *J* = 7.1 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 158.8, 157.1, 146.3, 139.9, 138.6, 137.1, 134.1, 130.7, 128.9, 128.7, 128.4, 126.5, 123.7, 117.2, 108.1, 44.4, 34.5, 20.8, 12.6; HRMS (ESI) *m/z* calcd for C₂₁H₂₀BrNNO₂ [M + Na]⁺: 420.0570, found 420.0572.

***N*-(2-Bromo-4-methylphenyl)-5-(2-chlorobenzyl)-*N*-ethylfuran-2-carboxamide (1v).** Colorless oil (1.29 g, 60% over 4 steps); IR (film) 2928, 1700, 1643, 1390, 1210, 824 cm⁻¹; ¹H NMR (400 MHz,

CDCl₃) δ 7.42 (s, 1H), 7.36–7.30 (m, 1H), 7.19–7.14 (m, 2H), 7.10 (s, 2H), 7.04–7.01 (m, 1H), 6.00 (br, 1H), 5.86 (br, 1H), 4.23–4.13 (m, 1H), 3.93 (s, 2H), 3.52–3.42 (m, 1H), 2.35 (s, 3H), 1.21 (t, *J* = 7.2 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 158.8, 155.3, 146.5, 139.9, 138.6, 134.9, 134.1, 133.8, 130.7, 130.6, 129.4, 128.9, 128.1, 126.9, 123.7, 117.2, 108.7, 44.4, 32.0, 20.8, 12.6; HRMS (ESI) *m/z* calcd for C₂₁H₁₉BrClNNO₂ [M + Na]⁺: 454.0180, found 454.0181.

***N*-(2-Bromo-5-methylphenyl)-5-(2-chlorobenzyl)-*N*-ethylfuran-2-carboxamide (1w).** Colorless oil (1.39 g, 66% over 4 steps); IR (film) 2967, 1701, 1642, 1472, 1211, 968 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 7.45 (d, *J* = 8.1 Hz, 1H), 7.35–7.30 (m, 1H), 7.21–7.13 (m, 2H), 7.08–6.96 (m, 3H), 6.05 (br, 1H), 5.87 (br, 1H), 4.21–4.11 (m, 1H), 3.92 (s, 2H), 3.57–3.47 (m, 1H), 2.29 (s, 3H), 1.23 (t, *J* = 7.1 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 158.6, 155.3, 146.5, 141.0, 138.5, 134.9, 133.9, 133.2, 131.5, 130.7, 130.3, 129.4, 128.1, 126.9, 120.6, 117.3, 108.7, 44.5, 32.0, 20.8, 12.7; HRMS (ESI) *m/z* calcd for C₂₁H₁₉BrClNNO₂ [M + Na]⁺: 454.0180, found 454.0183.

***N*-(2-Bromo-4-methoxyphenyl)-5-(2-chlorobenzyl)-*N*-ethylfuran-2-carboxamide (1x).** Colorless oil (1.36 g, 61% over 4 steps); IR (film) 2931, 1700, 1391, 1219, 969 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 7.37–7.29 (m, 1H), 7.21–7.15 (m, 2H), 7.14–7.09 (m, 2H), 7.05–7.01 (m, 1H), 6.83 (dd, *J* = 8.7, 1.9 Hz, 1H), 5.99 (br, 1H), 5.87 (br, 1H), 4.25–4.11 (m, 1H), 3.95 (s, 2H), 3.81 (d, *J* = 2.3 Hz, 3H), 3.49–3.36 (m, 1H), 1.20 (t, *J* = 7.1 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 159.6, 158.9, 155.4, 146.5, 134.9, 133.9, 133.8, 131.4, 130.7, 129.4, 128.1, 126.9, 124.6, 118.6, 117.2, 113.9, 108.7, 55.7, 44.4, 32.0, 12.6; HRMS (ESI) *m/z* calcd for C₂₁H₁₉BrClNNO₃ [M + Na]⁺: 470.0129, found 470.0129.

***N*-(2-Bromo-4-fluorophenyl)-*N*-ethyl-5-(4-methylbenzyl)furan-2-carboxamide (1y).** Colorless oil (1.03 g, 50% over 4 steps); IR (film) 2976, 1744, 1643, 1425, 1182, 976 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 7.49 (dd, *J* = 8.8, 5.7 Hz, 1H), 7.06 (d, *J* = 7.9 Hz, 2H), 6.96 (dd, *J* = 8.7, 2.9 Hz, 1H), 6.94–6.89 (m, 3H), 6.36 (d, *J* = 3.1 Hz, 1H), 5.89 (d, *J* = 3.1 Hz, 1H), 4.18–4.08 (m, 1H), 3.69 (s, 2H), 3.55–3.45 (m, 1H), 2.31 (s, 3H), 1.21 (t, *J* = 7.2 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 161.7 (d, *J*_{C-F} = 250.6 Hz), 158.5, 157.6, 146.3, 142.7 (d, *J*_{C-F} = 9.9 Hz), 136.2, 134.1 (d, *J*_{C-F} = 8.9 Hz), 133.9, 129.2, 128.5, 118.7, 118.3 (d, *J*_{C-F} = 22.7 Hz), 117.9, 116.6 (d, *J*_{C-F} = 22.1 Hz), 108.1, 44.6, 34.1, 21.0, 12.7; HRMS (ESI) *m/z* calcd for C₂₁H₁₉BrFNO₂ [M + Na]⁺: 438.0475, found 438.0472.

5-Benzyl-*N*-(2-bromobenzyl)-*N*-butylfuran-2-carboxamide (1ab). Colorless oil (1.06 g, 50% over 4 steps); IR (film) 2926, 1684, 1626, 1425, 1202, 965 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 7.53 (d, *J* = 7.1 Hz, 1H), 7.28–6.81 (m, 9H), 6.04 (br, 1H), 4.81 (s, 2H), 4.09–3.68 (m, 2H), 3.45 (s, 2H), 1.69–1.57 (m, 2H), 1.39–1.11 (m, 2H), 0.88 (t, *J* = 7.4 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 160.3, 156.8, 147.0, 137.0, 136.8, 136.7, 132.7, 128.7, 128.6, 128.4, 127.7, 126.7, 122.4, 118.0, 108.2, 47.7, 47.6, 34.7, 29.6, 20.1, 13.9; HRMS (ESI) *m/z* calcd for C₂₃H₂₄BrNNO₂ [M + Na]⁺: 448.0883, found 448.0882.

Method B. To a solution of 2-substituted furan **S5** (6 mmol) in anhydrous THF (6 mL), at –10 °C under nitrogen atmosphere, was added a solution of *n*-BuLi (2.1 mL, 1.6 M in hexane, 3.3 mmol). The solution was stirred for 1 h at the same temperature and then a solution of **S6** (3 mmol) in anhydrous THF (2 mL) was added. The reaction mixture was stirred for 30 min, then was quenched with saturated aq. NH₄Cl (4 mL). The organic solvent was evaporated under reduced pressure and the aqueous layer was extracted with ethyl acetate (3 × 5 mL). The combined organic layers were washed with saturated brine, dried over sodium sulfate, concentrated under reduced pressure to provide the crude product (**S7**) which was submitted to the next step without further purification.

The mixture of above-made crude product **S7**, R₂I (10 mmol), K₂CO₃ (1.2 g, 9 mmol) and CH₃CN (5 mL) was stirred at 80 °C under nitrogen atmosphere for 8 h. The reaction mixture was filtered and concentrated. The residue was purified by flash chromatography on a silica gel (using petroleum ether/ethyl acetate = 12:1 as the eluent) to give product **1** (**1r–t**, **1z**, and **1aa**).

***N*-(2-Bromo-4-(trifluoromethyl)phenyl)-*N*-ethyl-5-methylfuran-2-carboxamide (1r).** Colorless oil (0.63 g, 56% over 2 steps); IR (film) 2934, 1744, 1647, 1425, 1216, 960 cm⁻¹; ¹H NMR (400 MHz,

CDCl₃) δ 7.81 (d, J = 8.2 Hz, 1H), 7.54 (s, 1H), 7.51 (d, J = 8.2 Hz, 1H), 6.19 (br, 1H), 5.87 (br, 1H), 4.25–4.16 (m, 1H), 3.60–3.51 (m, 1H), 2.08 (s, 3H), 1.25 (t, J = 7.1 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 158.5, 155.1, 145.6, 142.4, 134.3, 130.9 (d, J_{C-F} = 33.6 Hz), 128.6, 128.1 (q, J_{C-F} = 4.0 Hz), 125.8 (q, J_{C-F} = 3.6 Hz), 123.2 (q, J_{C-F} = 273.4 Hz), 118.1, 107.7, 44.5, 13.4, 12.8; HRMS (ESI) m/z calcd for C₁₅H₁₄BrF₃NO₂ [M + H]⁺: 376.0155, found 376.0164.

***N*-(2-Bromophenyl)-5-ethyl-*N*-methylfuran-2-carboxamide (1s).** Colorless oil (0.54 g, 58% over 2 steps); IR (film) 2974, 1644, 1424, 1215, 946 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 7.69–7.64 (m, 1H), 7.41–7.32 (m, 1H), 7.31–7.22 (m, 2H), 6.03 (br, 1H), 5.84 (br, 1H), 3.34 (s, 3H), 2.46 (q, J = 7.3 Hz, 2H), 1.02 (t, J = 7.3 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 160.4, 159.3, 145.5, 143.3, 133.7, 130.1, 129.6, 128.7, 123.5, 117.4, 106.1, 36.9, 21.3, 11.6; HRMS (ESI) m/z calcd for C₁₄H₁₄BrNNaO₂ [M + Na]⁺: 330.0100, found 330.0099.

***N*-(2-Bromophenyl)-*N*,5-diethylfuran-2-carboxamide (1t).** Colorless oil (0.58 g, 60% over 2 steps); IR (film) 2976, 1642, 1471, 1211, 949 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 7.73–7.61 (m, 1H), 7.38–7.31 (m, 1H), 7.27–7.21 (m, 2H), 5.97 (br, 1H), 5.83 (br, 1H), 4.26–4.16 (m, 1H), 3.54–3.44 (m, 1H), 2.46 (q, J = 7.2 Hz, 2H), 1.22 (t, J = 7.2 Hz, 3H), 1.03 (t, J = 7.4 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 160.3, 158.8, 145.7, 141.6, 133.7, 131.2, 129.5, 128.3, 124.3, 117.3, 106.0, 44.4, 21.3, 12.7, 11.6; HRMS (ESI) m/z calcd for C₁₅H₁₆BrNNaO₂ [M + Na]⁺: 344.0257, found 344.0255.

***N*-(2-Bromophenyl)-*N*-ethyl-5-methylfuran-2-carboxamide (1z).** Colorless oil (0.46 g, 50% over 2 steps); IR (film) 2975, 1701, 1642, 1445, 1215, 961 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 7.68 (d, J = 8.0 Hz, 1H), 7.41–7.34 (m, 1H), 7.31–7.24 (m, 2H), 5.80 (br, 1H), 5.68 (br, 1H), 4.27–4.17 (m, 1H), 3.55–3.47 (m, 1H), 2.17 (s, 3H), 1.22 (t, J = 7.2 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 158.8, 154.9, 145.5, 141.4, 133.8, 131.3, 129.6, 128.4, 124.3, 117.1, 107.6, 44.3, 13.6, 12.7; HRMS (ESI) m/z calcd for C₁₄H₁₄BrNNaO₂ [M + Na]⁺: 330.0100, found 330.0099.

***N*-(2-Bromophenyl)-5-ethyl-*N*-isopropylfuran-2-carboxamide (1aa).** Colorless oil (0.42 g, 42% over 2 steps); IR (film) 2976, 1642, 1471, 1211, 949 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 7.65 (d, J = 7.9 Hz, 1H), 7.39 (t, J = 7.5 Hz, 1H), 7.32 (d, J = 7.8 Hz, 1H), 7.30–7.23 (m, 1H), 5.86 (br, 1H), 5.81 (br, 1H), 4.98–4.85 (m, 1H), 2.47 (q, J = 7.3 Hz, 2H), 1.38 (d, J = 6.8 Hz, 3H), 1.12 (d, J = 6.8 Hz, 3H), 1.04 (t, J = 7.3 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 160.1, 158.8, 146.1, 139.5, 133.7, 131.6, 129.5, 127.9, 126.3, 116.9, 105.9, 49.6, 21.9, 21.3, 19.1, 11.6; HRMS (ESI) m/z calcd for C₁₆H₁₈BrNNaO₂ [M + Na]⁺: 358.0413, found 358.0418.

General Procedure for the Preparation of 2 (Z-Isomer As the Major). To the mixture of K₂CO₃ (83 mg, 0.6 mmol), Pd(PPh₃)₄ (17 mg, 0.015 mmol, 5 mol %), and PPh₃ (8 mg, 0.03 mmol, 10 mol %) in a Schlenk flask was added a solution of 1 (0.3 mmol) in DCE (3 mL) under nitrogen atmosphere. The reaction was stirred at 80 °C for 12 h. H₂O (5 mL) was added to the reaction and the resulting mixture was extracted with ethyl acetate (3 × 5 mL). The combined organic extracts were washed with brine, dried over sodium sulfate, filtered and concentrated. The residue was purified by flash chromatography on a silica gel (using petroleum ether/ethyl acetate = 15:1 as the eluent) to give product 2 (Z-isomer as the major).

(Z)-5-Benzylidene-1'-ethyl-5H-spiro[furan-2,3'-indolin]-2'-one (2a). Colorless oil (82.7 mg, 91%, Z/E = 12/1); IR (film) 2925, 1730, 1650, 1368, 1214, 1023 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 7.61 (d, J = 7.4 Hz, 2H), 7.45–7.38 (m, 1H), 7.29–7.24 (m, 3H), 7.14–7.07 (m, 2H), 6.95 (d, J = 7.9 Hz, 1H), 6.66 (d, J = 5.7 Hz, 1H), 6.08 (d, J = 5.7 Hz, 1H), 5.60 (s, 1H), 3.93–3.71 (m, 2H), 1.37 (t, J = 7.2 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 172.1, 158.9, 142.9, 135.9, 130.9, 130.8, 130.5, 128.3, 128.2, 126.5, 125.7, 125.4, 123.2, 108.9, 101.1, 92.8, 35.3, 12.7; HRMS (ESI) m/z calcd for C₂₀H₁₈NO₂ [M + H]⁺: 304.1332, found 304.1339.

(Z)-5-Benzylidene-1'-ethyl-5'-methyl-5H-spiro[furan-2,3'-indolin]-2'-one (2b). Yellow solid (76 mg, 80%, Z/E = 13/1), mp 157.1–157.6 °C; IR (film) 2979, 2930, 1726, 1653, 1449, 1218, 1006 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 7.58 (d, J = 7.5 Hz, 2H), 7.26–7.20 (m, 2H), 7.18–7.14 (m, 1H), 7.11–7.06 (m, 1H), 7.04 (s, 1H), 6.80 (d, J = 8.0 Hz, 1H), 6.61 (d, J = 5.6 Hz, 1H), 6.04 (d, J = 5.6 Hz, 1H),

5.55 (s, 1H), 3.85–3.69 (m, 2H), 2.29 (s, 3H), 1.31 (t, J = 7.2 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 172.0, 159.1, 140.4, 135.9, 132.9, 131.1, 131.0, 130.4, 128.3, 128.2, 126.5, 126.2, 125.7, 108.6, 101.0, 93.0, 35.3, 20.9, 12.7; HRMS (ESI) m/z calcd for C₂₁H₂₀NO₂ [M + H]⁺: 318.1489, found 318.1500.

(Z)-5-Benzylidene-5'-tert-butyl-1'-ethyl-5H-spiro[furan-2,3'-indolin]-2'-one (2c). Colorless oil (88.3 mg, 82%, Z/E = 12/1); IR (film) 2979, 1724, 1610, 1449, 1217, 933 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 7.59 (d, J = 7.8 Hz, 2H), 7.40 (d, J = 8.2 Hz, 1H), 7.25–7.19 (m, 3H), 7.12–7.06 (m, 1H), 6.85 (d, J = 8.2 Hz, 1H), 6.63 (d, J = 5.6 Hz, 1H), 6.05 (d, J = 5.6 Hz, 1H), 5.57 (s, 1H), 3.83–3.73 (m, 2H), 1.32 (t, J = 7.2 Hz, 3H), 1.28 (s, 9H); ¹³C NMR (100 MHz, CDCl₃) δ 172.1, 159.1, 146.6, 140.5, 135.9, 131.1, 130.5, 128.2, 128.1, 127.5, 126.2, 125.6, 122.5, 108.4, 100.9, 93.1, 35.2, 34.6, 31.5, 12.7; HRMS (ESI) m/z calcd for C₂₄H₂₅NNaO₂ [M + Na]⁺: 382.1777, found 382.1786.

(Z)-5-Benzylidene-1'-ethyl-5'-methoxy-5H-spiro[furan-2,3'-indolin]-2'-one (2d). Colorless oil (74.9 mg, 75%, Z/E = 10/1); IR (film) 2977, 1728, 1458, 1218, 967 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 7.59–7.51 (m, 2H), 7.25–7.19 (m, 2H), 7.13 (d, J = 8.2 Hz, 1H), 7.08 (t, J = 7.4 Hz, 1H), 6.60 (d, J = 5.6 Hz, 1H), 6.57–6.51 (m, 1H), 6.48 (s, 1H), 6.01 (d, J = 5.6 Hz, 1H), 5.53 (s, 1H), 3.84 (s, 3H), 3.81–3.70 (m, 2H), 1.32 (t, J = 7.2 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 172.6, 162.3, 158.9, 144.4, 135.9, 130.9, 130.4, 128.2, 128.2, 126.4, 125.6, 118.3, 106.6, 100.9, 97.1, 92.7, 55.7, 35.3, 12.7; HRMS (ESI) m/z calcd for C₂₁H₂₀NO₃ [M + H]⁺: 334.1438, found 334.1450.

(Z)-5-Benzylidene-1'-ethyl-5'-fluoro-5H-spiro[furan-2,3'-indolin]-2'-one (2e). Colorless oil (87.6 mg, 91%, Z/E = 12/1); IR (film) 2981, 1728, 1654, 1455, 1213, 933 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 7.61 (d, J = 7.8 Hz, 2H), 7.32–7.25 (m, 2H), 7.17–7.06 (m, 2H), 7.01 (d, J = 7.2 Hz, 1H), 6.86 (d, J = 8.3, 3.1 Hz, 1H), 6.68 (d, J = 5.5 Hz, 1H), 6.07 (d, J = 5.5 Hz, 1H), 5.62 (s, 1H), 3.90–3.66 (m, 2H), 1.35 (t, J = 7.1 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 171.9, 159.1 (d, J_{C-F} = 243.4 Hz), 158.7, 138.7, 135.6, 130.9, 130.3, 128.3, 128.2, 128.1 (d, J_{C-F} = 7.6 Hz), 125.9, 117.2 (d, J_{C-F} = 23.7 Hz), 113.4 (d, J_{C-F} = 24.9 Hz), 109.5 (d, J_{C-F} = 7.7 Hz), 101.6, 92.6, 35.4, 12.6; HRMS (ESI) m/z calcd for C₂₀H₁₇FNO₂ [M + H]⁺: 322.1238, found 322.1249.

(Z)-1'-Ethyl-5-(4-methylbenzylidene)-5H-spiro[furan-2,3'-indolin]-2'-one (2f). Colorless oil (77.9 mg, 82%, Z/E = 10/1); IR (film) 2927, 1725, 1655, 1475, 1214, 933 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 7.46 (d, J = 7.4 Hz, 2H), 7.41–7.32 (m, 1H), 7.22 (d, J = 7.3 Hz, 1H), 7.08–7.01 (m, 3H), 6.91 (d, J = 7.8 Hz, 1H), 6.63 (d, J = 5.7 Hz, 1H), 6.00 (d, J = 5.7 Hz, 1H), 5.53 (s, 1H), 3.89–3.65 (m, 2H), 2.28 (s, 3H), 1.33 (t, J = 6.8 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 172.2, 158.4, 142.9, 135.4, 132.9, 130.8, 130.5, 130.3, 128.9, 128.2, 126.7, 125.4, 108.8, 101.1, 92.7, 35.3, 21.2, 12.7; HRMS (ESI) m/z calcd for C₂₁H₂₀NO₂ [M + H]⁺: 318.1487, found 318.1497.

(Z)-1'-Ethyl-5'-methyl-5-(4-methylbenzylidene)-5H-spiro[furan-2,3'-indolin]-2'-one (2g). Colorless oil (71.5 mg, 72%, Z/E = 16/1); IR (film) 2979, 1724, 1655, 1449, 1217, 933 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 7.51 (d, J = 8.1 Hz, 2H), 7.20 (d, J = 7.9 Hz, 1H), 7.13–7.05 (m, 3H), 6.83 (d, J = 7.9 Hz, 1H), 6.64 (d, J = 5.7 Hz, 1H), 6.04 (d, J = 5.7 Hz, 1H), 5.57 (s, 1H), 3.91–3.70 (m, 2H), 2.33 (s, 3H), 2.32 (s, 3H), 1.35 (t, J = 7.2 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 172.1, 158.5, 140.4, 135.4, 133.0, 132.9, 130.9, 130.6, 130.4, 128.9, 128.2, 126.7, 126.2, 108.6, 100.9, 92.9, 35.3, 21.2, 20.9, 12.7; HRMS (ESI) m/z calcd for C₂₂H₂₂NO₂ [M + H]⁺: 332.1645, found 332.1655.

(Z)-1'-Ethyl-5'-methoxy-5-(4-methylbenzylidene)-5H-spiro[furan-2,3'-indolin]-2'-one (2h). Colorless oil (83.3 mg, 80%, Z/E = 14/1); IR (film) 2934, 1728, 1618, 1459, 1218, 966 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 7.46 (d, J = 8.1 Hz, 2H), 7.12 (d, J = 8.2 Hz, 1H), 7.03 (d, J = 8.1 Hz, 2H), 6.58 (d, J = 5.6 Hz, 1H), 6.53 (d, J = 8.2, 1H), 6.47 (s, 1H), 5.97 (d, J = 5.6 Hz, 1H), 5.50 (s, 1H), 3.83 (s, 3H), 3.81–3.70 (m, 2H), 2.28 (s, 3H), 1.31 (t, J = 7.2 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 172.7, 162.3, 158.3, 144.4, 135.3, 133.1, 130.5, 130.4, 128.9, 128.2, 126.4, 118.5, 106.5, 100.9, 97.1, 92.6, 55.7, 35.3, 21.2, 12.7; HRMS (ESI) m/z calcd for C₂₂H₂₂NO₃ [M + H]⁺: 348.1594, found 348.1603.

(*Z*)-1'-Ethyl-6'-methyl-5-(4-methylbenzylidene)-5H-spiro[furan-2,3'-indolin]-2'-one (**2i**). Colorless oil, (69.5 mg, 70%, *Z/E* = 8/1); IR (film) 3854, 3740, 3433, 2358, 1775, 1728, 1618, 1505, 1459, 1370, 1274, 1218, 1171, 1099, 1043, 966, 832, 753, 638, 582, 518, 465 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 7.46 (d, *J* = 7.7 Hz, 2H), 7.09 (d, *J* = 7.5 Hz, 1H), 7.03 (d, *J* = 7.7 Hz, 2H), 6.86 (d, *J* = 7.5 Hz, 1H), 6.72 (s, 1H), 6.59 (d, *J* = 5.6 Hz, 1H), 5.98 (d, *J* = 5.6 Hz, 1H), 5.51 (s, 1H), 3.86–3.68 (m, 2H), 2.40 (s, 3H), 2.27 (s, 3H), 1.32 (t, *J* = 7.2 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 172.4, 158.4, 143.0, 141.3, 135.3, 133.0, 130.4, 130.4, 128.8, 128.1, 125.2, 123.7, 123.6, 109.7, 100.9, 92.6, 35.2, 22.0, 21.2, 12.7; HRMS (ESI) *m/z* calcd for C₂₂H₂₁NNaO₂ [M + Na]⁺: 354.1464, found 354.1470.

(*Z*)-5-(4-Chlorobenzylidene)-1'-ethyl-5H-spiro[furan-2,3'-indolin]-2'-one (**2j**). Colorless oil (83.9 mg, 83%, *Z/E* = 14/1); IR (film) 2980, 1725, 1654, 1480, 1272, 1096, 934 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 7.49 (d, *J* = 8.6 Hz, 2H), 7.41–7.36 (m, 1H), 7.23–7.16 (m, 3H), 7.10–7.04 (m, 1H), 6.92 (d, *J* = 7.9 Hz, 1H), 6.62 (d, *J* = 5.7 Hz, 1H), 6.07 (d, *J* = 5.7 Hz, 1H), 5.51 (s, 1H), 3.86–3.74 (m, 2H), 1.33 (t, *J* = 7.2 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 171.9, 159.3, 142.9, 134.4, 131.4, 131.0, 130.9, 130.3, 129.4, 128.3, 126.3, 125.4, 123.2, 108.9, 99.9, 92.9, 35.3, 12.7; HRMS (ESI) *m/z* calcd for C₂₀H₁₇ClNO₂ [M + H]⁺: 338.0942, found 338.0951.

(*Z*)-5-(4-Chlorobenzylidene)-1'-ethyl-5'-methyl-5H-spiro[furan-2,3'-indolin]-2'-one (**2k**). Colorless oil (84.2 mg, 80%, *Z/E* = 13/1); IR (film) 2979, 1722, 1653, 1456, 1272, 934; ¹H NMR (400 MHz, CDCl₃) δ 7.50 (d, *J* = 8.4 Hz, 2H), 7.21–7.15 (m, 3H), 7.03 (s, 1H), 6.81 (d, *J* = 8.0 Hz, 1H), 6.61 (d, *J* = 5.7 Hz, 1H), 6.07 (d, *J* = 5.7 Hz, 1H), 5.51 (s, 1H), 3.84–3.69 (m, 2H), 2.30 (s, 3H), 1.32 (t, *J* = 7.2 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 171.8, 159.4, 140.4, 134.4, 133.0, 131.6, 131.2, 130.9, 130.2, 129.4, 128.3, 126.2, 126.1, 108.7, 99.9, 93.1, 35.3, 20.9, 12.7; HRMS (ESI) *m/z* calcd for C₂₁H₁₉ClNO₂ [M + H]⁺: 352.1099, found 352.1107.

(*Z*)-1'-Ethyl-5-(4-methoxybenzylidene)-5'-methyl-5H-spiro[furan-2,3'-indolin]-2'-one (**2l**). Colorless oil (83.3 mg, 80%, *Z/E* = 9/1); IR (film) 2933, 1722, 1453, 1251, 931 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 7.55 (d, *J* = 8.8 Hz, 2H), 7.19 (d, *J* = 7.9 Hz, 1H), 7.07 (s, 1H), 6.87–6.75 (m, 3H), 6.63 (d, *J* = 5.7 Hz, 1H), 6.00 (d, *J* = 5.7 Hz, 1H), 5.54 (s, 1H), 3.84–3.74 (m, 2H), 3.79 (s, 3H), 2.32 (s, 3H), 1.35 (t, *J* = 7.2 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 172.2, 157.7, 157.6, 140.4, 132.9, 130.9, 130.3, 129.9, 129.5, 128.8, 126.8, 126.2, 113.7, 108.6, 100.5, 92.8, 55.2, 35.3, 20.9, 12.7; HRMS (ESI) *m/z* calcd for C₂₂H₂₂NO₃ [M + H]⁺: 348.1594, found 348.1606.

(*Z*)-1'-Ethyl-5-(2-methylbenzylidene)-5H-spiro[furan-2,3'-indolin]-2'-one (**2m**). Colorless oil (82.7 mg, 87%, *Z/E* = 10/1); IR (film) 2931, 1724, 1473, 1214, 933 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 7.93 (d, *J* = 7.7 Hz, 1H), 7.39–7.31 (m, 1H), 7.25–7.20 (m, 1H), 7.12–6.97 (m, 4H), 6.89 (d, *J* = 7.8 Hz, 1H), 6.66 (d, *J* = 5.6 Hz, 1H), 6.03 (d, *J* = 5.6 Hz, 1H), 5.66 (s, 1H), 3.82–3.73 (m, 2H), 2.35 (s, 3H), 1.31 (t, *J* = 7.2 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 172.1, 158.9, 142.9, 134.9, 134.2, 130.8, 130.8, 130.7, 129.8, 128.7, 126.6, 125.9, 125.8, 125.4, 123.1, 108.8, 97.9, 92.6, 35.3, 20.3, 12.7; HRMS (ESI) *m/z* calcd for C₂₁H₂₀NO₂ [M + H]⁺: 318.1489, found 318.1497.

(*Z*)-5-(2-Chlorobenzylidene)-1'-ethyl-5H-spiro[furan-2,3'-indolin]-2'-one (**2n**). Colorless oil (85.9 mg, 85%, *Z/E* = 11/1); IR (film) 2980, 1777, 1654, 1480, 1215, 934 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 8.09 (d, *J* = 7.9 Hz, 1H), 7.44–7.38 (m, 1H), 7.34 (d, *J* = 7.9 Hz, 1H), 7.25 (d, *J* = 7.3 Hz, 1H), 7.17–7.07 (m, 2H), 7.06–7.02 (m, 1H), 6.94 (d, *J* = 7.9 Hz, 1H), 6.73 (d, *J* = 5.5 Hz, 1H), 6.14 (d, *J* = 5.5 Hz, 1H), 6.03 (s, 1H), 3.91–3.76 (m, 2H), 1.36 (t, *J* = 7.1 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 171.7, 160.2, 142.9, 133.4, 131.9, 131.7, 130.9, 130.7, 129.8, 129.1, 126.6, 126.5, 126.1, 125.4, 123.2, 108.9, 96.5, 92.9, 35.3, 12.6; HRMS (ESI) *m/z* calcd for C₂₀H₁₆ClNNaO₂ [M + Na]⁺: 360.0762, found 360.0768.

(*Z*)-1'-Ethyl-5'-methyl-5-(thiophen-2-ylmethylene)-5H-spiro[furan-2,3'-indolin]-2'-one (**2o**). Colorless oil (83.3 mg, 86%, *Z/E* = 12/1); IR (film) 2978, 1726, 1461, 1218, 936 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 7.16 (d, *J* = 7.9 Hz, 1H), 7.13–7.07 (m, 2H), 7.03 (s, 1H), 6.96–6.90 (m, 1H), 6.80 (d, *J* = 8.0 Hz, 1H), 6.60 (d, *J* = 5.7 Hz, 1H), 6.05 (d, *J* = 5.7 Hz, 1H), 5.86 (s, 1H), 3.85–3.67 (m, 2H), 2.29 (s, 3H), 1.31 (t, *J* = 7.2 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ

171.8, 157.5, 140.4, 138.9, 132.9, 131.5, 131.1, 129.1, 126.9, 126.4, 126.1, 125.2, 123.9, 108.6, 94.9, 92.9, 35.3, 20.9, 12.7; HRMS (ESI) *m/z* calcd for C₁₉H₁₈NO₂S [M + H]⁺: 324.1053, found 324.1062.

(*Z*)-1'-Ethyl-5-(naphthalen-2-ylmethylene)-5H-spiro[furan-2,3'-indolin]-2'-one (**2p**). Colorless oil (92.4 mg, 87%, *Z/E* = 13/1); IR (film) 2934, 1728, 1653, 1471, 1270, 935 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 7.96 (s, 1H), 7.80–7.65 (m, 4H), 7.42–7.31 (m, 3H), 7.25 (br, 1H), 7.13–7.05 (m, 1H), 6.93 (d, *J* = 7.9 Hz, 1H), 6.68 (d, *J* = 5.6 Hz, 1H), 6.08 (d, *J* = 5.6 Hz, 1H), 5.72 (s, 1H), 3.88–3.76 (m, 2H), 1.35 (t, *J* = 7.2 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 172.1, 159.4, 142.9, 133.7, 133.5, 131.9, 131.0, 130.9, 130.6, 127.9, 127.6, 127.5, 127.0, 126.6, 126.5, 125.7, 125.5, 125.2, 123.2, 108.9, 101.4, 92.9, 35.3, 12.7; HRMS (ESI) *m/z* calcd for C₂₄H₂₀NO₂ [M + H]⁺: 354.1489, found 354.1501.

(*Z*)-1'-Ethyl-5'-methyl-5-(naphthalen-2-ylmethylene)-5H-spiro[furan-2,3'-indolin]-2'-one (**2q**). Colorless solid (93.6 mg, 85%, *Z/E* = 12/1), mp 186.5–187.2 °C; IR (film) 2977, 1726, 1653, 1448, 1272, 936 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 7.97 (s, 1H), 7.80–7.65 (m, 4H), 7.40–7.32 (m, 2H), 7.18 (d, *J* = 7.9 Hz, 1H), 7.07 (s, 1H), 6.82 (d, *J* = 8.0 Hz, 1H), 6.67 (d, *J* = 5.6 Hz, 1H), 6.07 (d, *J* = 5.6 Hz, 1H), 5.71 (s, 1H), 3.86–3.74 (m, 2H), 2.30 (s, 3H), 1.34 (t, *J* = 7.2 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 171.9, 159.5, 140.4, 133.7, 133.6, 132.9, 131.9, 131.3, 131.1, 130.4, 127.9, 127.6, 127.5, 127.0, 126.5, 126.5, 125.7, 125.1, 108.7, 101.2, 93.2, 35.3, 20.9, 12.7; HRMS (ESI) *m/z* calcd for C₂₃H₂₂NO₂ [M + H]⁺: 368.1645, found 368.1654.

(*Z*)-1'-Ethyl-5-methylene-5'-(trifluoromethyl)-5H-spiro[furan-2,3'-indolin]-2'-one (**2r**). Colorless oil (81.4 mg, 92%); IR (film) 2985, 1729, 1626, 1452, 1213, 948 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 7.38–7.29 (m, 2H), 7.07 (s, 1H), 6.59 (d, *J* = 5.7 Hz, 1H), 6.02 (d, *J* = 5.7 Hz, 1H), 4.53 (s, 1H), 4.26 (s, 1H), 3.84–3.71 (m, 2H), 1.32 (t, *J* = 7.2 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 171.9, 163.9, 143.5, 133.0 (q, *J*_{C-F} = 32.7 Hz), 131.9, 130.2, 129.4, 125.6, 123.6 (q, *J*_{C-F} = 273.8 Hz), 120.2 (q, *J*_{C-F} = 4.1 Hz), 105.5 (d, *J*_{C-F} = 3.9 Hz), 90.6, 83.9, 35.4, 12.4; HRMS (ESI) *m/z* calcd for C₁₅H₁₃F₃NO₂ [M + H]⁺: 296.0893, found 296.0900.

(*Z*)-5-Ethylidene-1'-methyl-5H-spiro[furan-2,3'-indolin]-2'-one (**2s**). Colorless oil (57.9 mg, 85%, *Z/E* = 4/1); IR (film) 2977, 1721, 1625, 1461, 1212, 966 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 7.41–7.35 (m, 1H), 7.24 (d, *J* = 7.3 Hz, 1H), 7.14–7.06 (m, 1H), 6.87 (d, *J* = 7.8 Hz, 1H), 6.49 (d, *J* = 5.7 Hz, 1H), 5.88 (d, *J* = 5.7 Hz, 1H), 4.62 (q, *J* = 7.1 Hz, 1H), 3.24 (s, 3H), 1.73 (d, *J* = 7.1 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 173.4, 158.7, 143.7, 130.6, 129.3, 129.0, 127.1, 125.1, 123.3, 108.6, 94.9, 90.9, 26.6, 10.7; HRMS (ESI) *m/z* calcd for C₁₄H₁₄NO₂ [M + H]⁺: 228.1019, found 228.1015.

(*Z*)-1'-Ethyl-5-ethylidene-5H-spiro[furan-2,3'-indolin]-2'-one (**2t**). Colorless oil (59.3 mg, 82%, *Z/E* = 5/1); IR (film) 2977, 2935, 1721, 1611, 1461, 1212, 966 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 7.31–7.27 (m, 1H), 7.24 (d, *J* = 7.3 Hz, 1H), 7.13–7.05 (m, 1H), 6.89 (d, *J* = 7.8 Hz, 1H), 6.48 (d, *J* = 5.7 Hz, 1H), 5.88 (d, *J* = 5.7 Hz, 1H), 4.61 (q, *J* = 7.1 Hz, 1H), 3.81–3.74 (m, 2H), 1.74 (d, *J* = 7.1 Hz, 3H), 1.32 (t, *J* = 7.1 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 172.9, 158.7, 142.8, 135.8, 130.5, 128.9, 127.3, 125.2, 123.1, 113.6, 108.7, 94.8, 35.1, 12.5, 8.8; HRMS (ESI) *m/z* calcd for C₁₅H₁₆NO₂ [M + H]⁺: 242.1176, found 242.1180.

(*Z*)-5-Ethylidene-1'-isopropyl-5H-spiro[furan-2,3'-indolin]-2'-one (**2u**). Colorless oil (39.1 mg, 51%, *Z/E* = 4/1); IR (film) 2975, 1707, 1609, 1468, 1210, 979 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 7.35–7.27 (m, 1H), 7.21 (d, *J* = 7.3 Hz, 1H), 7.06–6.99 (m, 2H), 6.45 (d, *J* = 5.7 Hz, 1H), 5.84 (d, *J* = 5.7 Hz, 1H), 4.61 (q, *J* = 7.1 Hz, 1H), 4.62–4.52 (m, 1H), 1.72 (d, *J* = 7.1 Hz, 3H), 1.51 (d, *J* = 2.0 Hz, 3H), 1.49 (d, *J* = 2.0 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 172.9, 158.8, 142.3, 130.3, 129.5, 128.8, 127.6, 125.3, 122.6, 110.2, 94.6, 90.7, 44.3, 19.4, 19.2, 10.7; HRMS (ESI) *m/z* calcd for C₁₆H₁₇NNaO₂ [M + Na]⁺: 278.1151, found 278.1149.

(*Z*)-5-Benzylidene-2'-butyl-1'H,5H-spiro[furan-2,4'-isoquinolin]-3'(2'H)-one (**2w**). Colorless oil (62.1 mg, 60%, *Z/E* = 12/1); IR (film) 2929, 1654, 1461, 1263, 941 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 7.68 (d, *J* = 7.3 Hz, 2H), 7.41 (d, *J* = 7.3 Hz, 1H), 7.35 (d, *J* = 8.1 Hz, 2H), 7.33–7.28 (m, 3H), 7.15–7.11 (m, 1H), 6.48 (d, *J* = 5.6 Hz,

1H), 6.26 (d, $J = 5.6$ Hz, 1H), 5.56 (s, 1H), 4.64 (s, 2H), 3.67–3.48 (m, 2H), 1.71–1.66 (m, 2H), 1.44–1.36 (m, 2H), 0.97 (t, $J = 7.1$ Hz, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 166.3, 159.0, 136.2, 134.7, 132.5, 130.6, 128.5, 128.4, 128.2, 127.7, 125.8, 125.4, 125.2, 100.6, 99.9, 91.7, 49.9, 47.5, 29.3, 20.0, 13.8; HRMS (ESI) m/z calcd for $\text{C}_{23}\text{H}_{23}\text{NNaO}_2$ $[\text{M} + \text{Na}]^+$: 368.1621, found 368.1619.

General Procedure for the Preparation of 2 (E-isomer As the Major). To the mixture of *t*-BuOLi (48 mg, 0.6 mmol), Pd(PPh_3)₄ (17 mg, 0.015 mmol, 5 mol %), and PPh_3 (8 mg, 0.03 mmol, 10 mol %) in a Schlenk flask was added a solution of **1** (0.3 mmol) in 1,4-dioxane (3 mL) under nitrogen atmosphere. The reaction was stirred at 80 °C for 12 h. H_2O (5 mL) was added to the reaction and the resulting mixture was extracted with EtOAc (3 × 5 mL). The combined organic extracts were washed with brine, dried over Na_2SO_4 , filtered and concentrated. The residue was purified by flash chromatography on a silica gel (using PE/EtOAc = 15:1 as the eluent) to give product **2** (E-isomer as the major).

(E)-5-Benzylidene-1'-ethyl-5H-spiro[furan-2,3'-indolin]-2'-one (2a). Colorless oil (47.2 mg, 50%, $Z/E = 1/2.7$); IR (film) 2925, 1730, 1650, 1263, 1023 cm^{-1} ; ^1H NMR (400 MHz, CDCl_3) δ 7.41 (dd, $J = 7.8, 1.2$ Hz, 1H), 7.35–7.34 (m, 3H), 7.30–7.25 (m, 2H), 7.24–7.17 (m, 1H), 7.14–7.08 (m, 2H), 6.92 (d, $J = 7.9$ Hz, 1H), 6.21 (d, $J = 5.8$ Hz, 1H), 6.16 (s, 1H), 3.85–3.77 (m, 2H), 1.34 (t, $J = 7.2$ Hz, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 172.1, 159.9, 142.9, 136.4, 134.3, 130.9, 128.5, 127.8, 126.3, 126.2, 125.8, 125.3, 123.2, 108.9, 101.7, 90.3, 35.2, 12.5; HRMS (ESI) m/z calcd for $\text{C}_{20}\text{H}_{17}\text{NNaO}_2$ $[\text{M} + \text{Na}]^+$: 326.1151, found 326.1152.

(E)-1'-Ethyl-5'-methyl-5-(4-methylbenzylidene)-5H-spiro[furan-2,3'-indolin]-2'-one (2g'). Colorless oil (64.5 mg, 65%, $Z/E = 1/2.1$); IR (film) 2925, 1724, 1612, 1455, 1217, 933 cm^{-1} ; ^1H NMR (400 MHz, CDCl_3) δ 7.23 (d, $J = 7.8$ Hz, 2H), 7.17–7.11 (m, 3H), 7.08 (d, $J = 5.7$ Hz, 1H), 6.91 (d, $J = 7.5$ Hz, 1H), 6.73 (s, 1H), 6.15 (d, $J = 5.7$ Hz, 1H), 6.11 (s, 1H), 3.82–3.72 (m, 2H), 2.42 (s, 3H), 2.36 (s, 3H), 1.33 (t, $J = 7.2$ Hz, 3H). ^{13}C NMR (100 MHz, CDCl_3) δ 172.5, 159.5, 142.9, 141.3, 135.4, 133.9, 133.5, 129.2, 127.6, 126.2, 125.1, 123.6, 123.3, 109.7, 101.4, 90.1, 35.1, 22.0, 21.1, 12.6; HRMS (ESI) m/z calcd for $\text{C}_{22}\text{H}_{21}\text{NNaO}_2$ $[\text{M} + \text{Na}]^+$: 354.1464, found 354.1469.

(E)-1'-Ethyl-5'-methoxy-5-(4-methylbenzylidene)-5H-spiro[furan-2,3'-indolin]-2'-one (2h'). Colorless oil (52.1 mg, 50%, $Z/E = 1/1.5$); IR (film) 2928, 1722, 1648, 1461, 1278, 1033 cm^{-1} ; ^1H NMR (400 MHz, CDCl_3) δ 7.24 (d, $J = 7.5$ Hz, 2H), 7.15 (d, $J = 7.5$ Hz, 2H), 7.09 (d, $J = 5.7$ Hz, 1H), 6.91 (d, $J = 8.5$ Hz, 1H), 6.86 (s, 1H), 6.82 (d, $J = 8.5$ Hz, 1H), 6.18 (d, $J = 5.7$ Hz, 1H), 6.13 (s, 1H), 3.80 (s, 3H), 3.78–3.72 (m, 2H), 2.37 (s, 3H), 1.33 (d, $J = 7.1$ Hz, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 171.9, 159.4, 156.4, 136.0, 135.5, 133.9, 133.4, 129.2, 127.6, 127.5, 126.3, 115.8, 111.8, 109.4, 101.7, 90.4, 55.9, 35.2, 21.1, 12.5; HRMS (ESI) m/z calcd for $\text{C}_{22}\text{H}_{21}\text{NNaO}_3$ $[\text{M} + \text{Na}]^+$: 370.1414, found 370.1418.

(E)-1'-Ethyl-6'-methyl-5-(4-methylbenzylidene)-5H-spiro[furan-2,3'-indolin]-2'-one (2i'). Colorless oil (67.5 mg, 68%, $Z/E = 1/2$); IR (film) 2926, 1725, 1619, 1451, 1218, 1018 cm^{-1} ; ^1H NMR (400 MHz, CDCl_3) δ 7.23 (d, $J = 7.4$ Hz, 2H), 7.21–7.14 (m, 3H), 7.12–7.07 (m, 2H), 6.80 (d, $J = 7.9$ Hz, 1H), 6.17 (d, $J = 5.8$ Hz, 1H), 6.13 (s, 1H), 3.81–3.74 (m, 2H), 2.37 (s, 3H), 2.34 (s, 3H), 1.32 (t, $J = 7.2$ Hz, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 172.1, 159.5, 140.4, 135.5, 134.0, 133.5, 132.9, 131.0, 129.2, 127.6, 126.3, 126.2, 125.9, 108.6, 101.5, 90.3, 35.2, 21.1, 20.9, 12.6; HRMS (ESI) m/z calcd for $\text{C}_{22}\text{H}_{21}\text{NNaO}_2$ $[\text{M} + \text{Na}]^+$: 354.1464, found 354.1469.

General Procedure for the Preparation of 3. To the mixture of Cs_2CO_3 (146 mg, 0.45 mmol), PivOH (9.2 mg, 0.09 mmol), PdCl₂ (2.65 mg, 0.015 mmol, 5 mol %), L₃ (10.5 mg, 0.03 mmol, 10 mol %), and toluene (3 mL) in a Schlenk flask was added a solution of **1** (0.3 mmol) in toluene (3 mL) under nitrogen atmosphere. The reaction was stirred at 80 °C until the disappearance of the starting material according to the TLC. H_2O (5 mL) was added to the reaction and the resulting mixture was extracted with ethyl acetate (3 × 5 mL). The combined organic extracts were washed with brine, dried over sodium sulfate, filtered and concentrated. The residue was purified by flash chromatography on a silica gel (using petroleum ether/ethyl acetate = 8:1 as the eluent) to give product **3**.

2-Benzyl-5-ethylfuro[2,3-*c*]quinolin-4(5H)-one (3a). Colorless oil (74.5 mg, 82%); IR (film) 2976, 1665, 1449, 1257, 956 cm^{-1} ; ^1H NMR (400 MHz, CDCl_3) δ 7.75 (d, $J = 7.8$ Hz, 1H), 7.55–7.48 (m, 1H), 7.45 (d, $J = 8.6$ Hz, 1H), 7.39–7.33 (m, 4H), 7.32–7.23 (m, 2H), 6.60 (s, 1H), 4.48 (q, $J = 7.0$ Hz, 2H), 4.19 (s, 2H), 1.40 (t, $J = 7.0$ Hz, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 161.9, 153.2, 141.6, 136.8, 136.5, 130.6, 129.0, 128.8, 128.6, 127.0, 124.7, 122.1, 116.9, 115.1, 102.6, 37.0, 35.0, 13.1; HRMS (ESI) m/z calcd for $\text{C}_{20}\text{H}_{17}\text{NNaO}_2$ $[\text{M} + \text{Na}]^+$: 326.1151, found 326.1153.

2-Benzyl-5-ethyl-8-methylfuro[2,3-*c*]quinolin-4(5H)-one (3b). Colorless oil (76.1 mg, 80%); IR (film) 2975, 1664, 1450, 1212, 960 cm^{-1} ; ^1H NMR (400 MHz, CDCl_3) δ 7.55 (s, 1H), 7.39–7.32 (m, 6H), 7.30 (dd, $J = 7.3, 4.9$ Hz, 1H), 6.57 (s, 1H), 4.46 (q, $J = 7.1$ Hz, 2H), 4.19 (s, 2H), 2.44 (s, 3H), 1.39 (t, $J = 7.1$ Hz, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 161.8, 153.1, 141.7, 136.5, 134.7, 131.7, 130.4, 129.8, 129.1, 128.8, 127.0, 124.6, 116.8, 114.9, 102.5, 37.0, 35.1, 20.7, 13.2; HRMS (ESI) m/z calcd for $\text{C}_{21}\text{H}_{19}\text{NNaO}_2$ $[\text{M} + \text{Na}]^+$: 340.1308, found 340.1309.

2-Benzyl-5-ethyl-7-methylfuro[2,3-*c*]quinolin-4(5H)-one (3c). Colorless oil (74.2 mg, 78%); IR (film) 2974, 1665, 1456, 1260, 959 cm^{-1} ; ^1H NMR (400 MHz, CDCl_3) δ 7.64 (d, $J = 7.9$ Hz, 1H), 7.40–7.32 (m, 4H), 7.32–7.27 (m, 1H), 7.25 (s, 1H), 7.10 (d, $J = 7.9$ Hz, 1H), 6.57 (s, 1H), 4.47 (q, $J = 7.1$ Hz, 2H), 4.19 (s, 2H), 2.52 (s, 3H), 1.40 (t, $J = 7.1$ Hz, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 161.9, 153.3, 141.2, 138.8, 136.9, 136.5, 130.7, 129.1, 128.8, 127.0, 124.5, 123.5, 115.3, 114.5, 102.5, 36.9, 35.0, 22.2, 13.1; HRMS (ESI) m/z calcd for $\text{C}_{21}\text{H}_{19}\text{NNaO}_2$ $[\text{M} + \text{Na}]^+$: 340.1308, found 340.1312.

2-Benzyl-8-tert-butyl-5-ethylfuro[2,3-*c*]quinolin-4(5H)-one (3d). Colorless oil (86.2 mg, 80%); IR (film) 2962, 1665, 1451, 1215, 960 cm^{-1} ; ^1H NMR (400 MHz, CDCl_3) δ 7.71 (s, 1H), 7.56 (dd, $J = 9.0, 2.3$ Hz, 1H), 7.39 (d, $J = 9.0$ Hz, 1H), 7.38–7.31 (m, 4H), 7.31–7.25 (m, 1H), 6.62 (s, 1H), 4.46 (q, $J = 7.1$ Hz, 2H), 4.19 (s, 2H), 1.40 (t, $J = 7.1$ Hz, 3H), 1.37 (s, 9H); ^{13}C NMR (100 MHz, CDCl_3) δ 161.8, 153.2, 145.2, 141.7, 136.5, 134.7, 130.8, 129.1, 128.8, 127.0, 126.3, 120.8, 116.5, 114.9, 102.5, 37.0, 35.1, 34.4, 31.4, 13.2; HRMS (ESI) m/z calcd for $\text{C}_{24}\text{H}_{25}\text{NNaO}_2$ $[\text{M} + \text{Na}]^+$: 382.1777, found 382.1782.

2-(2-Chlorobenzyl)-5-ethylfuro[2,3-*c*]quinolin-4(5H)-one (3e). Brown solid (75.8 mg, 75%), mp 115.2–116.0 °C; IR (film) 2975, 1665, 1445, 1211, 955 cm^{-1} ; ^1H NMR (400 MHz, CDCl_3) δ 7.75 (dd, $J = 7.8, 1.3$ Hz, 1H), 7.56–7.48 (m, 1H), 7.45 (d, $J = 8.4$ Hz, 1H), 7.42–7.39 (m, 1H), 7.38–7.32 (m, 1H), 7.28–7.23 (m, 3H), 6.60 (s, 1H), 4.47 (q, $J = 7.1$ Hz, 2H), 4.32 (s, 2H), 1.39 (t, $J = 7.1$ Hz, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 160.1, 153.2, 141.7, 136.8, 134.4, 134.2, 131.2, 130.6, 129.8, 128.7, 128.6, 127.2, 124.8, 122.2, 116.9, 115.1, 103.0, 37.1, 32.7, 13.1; HRMS (ESI) m/z calcd for $\text{C}_{20}\text{H}_{16}\text{ClNNaO}_2$ $[\text{M} + \text{Na}]^+$: 360.0762, found 360.0763.

2-(2-Chlorobenzyl)-5-ethyl-8-methylfuro[2,3-*c*]quinolin-4(5H)-one (3f). Colorless solid (76.9 mg, 73%), mp 137.4–137.5 °C; IR (film) 2975, 1664, 1212, 1042 cm^{-1} ; ^1H NMR (400 MHz, CDCl_3) δ 7.54 (s, 1H), 7.41 (dd, $J = 5.8, 3.5$ Hz, 1H), 7.36 (dd, $J = 5.9, 3.4$ Hz, 1H), 7.35–7.29 (m, 2H), 7.27–7.21 (m, 2H), 6.57 (s, 1H), 4.44 (q, $J = 7.1$ Hz, 2H), 4.31 (s, 2H), 2.42 (s, 3H), 1.37 (t, $J = 7.1$ Hz, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 159.9, 153.1, 141.8, 134.7, 134.4, 134.2, 131.8, 131.2, 130.4, 129.8, 129.7, 128.7, 127.2, 124.7, 116.7, 114.9, 102.9, 37.0, 32.8, 20.6, 13.1; HRMS (ESI) m/z calcd for $\text{C}_{21}\text{H}_{18}\text{ClNNaO}_2$ $[\text{M} + \text{Na}]^+$: 374.0918, found 374.0921.

2-(2-Chlorobenzyl)-5-ethyl-7-methylfuro[2,3-*c*]quinolin-4(5H)-one (3g). Colorless solid (84.2 mg, 80%), mp 146.2–146.3 °C; IR (film) 2975, 1665, 1460, 1210, 957 cm^{-1} ; ^1H NMR (400 MHz, CDCl_3) δ 7.65 (d, $J = 7.9$ Hz, 1H), 7.46–7.40 (m, 1H), 7.39–7.34 (m, 1H), 7.29–7.24 (m, 3H), 7.10 (d, $J = 7.9$ Hz, 1H), 6.58 (s, 1H), 4.47 (q, $J = 7.1$ Hz, 2H), 4.32 (s, 2H), 2.52 (s, 3H), 1.40 (t, $J = 7.1$ Hz, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 159.9, 153.3, 141.3, 138.9, 136.9, 134.4, 134.2, 131.2, 130.6, 129.7, 128.6, 127.2, 124.6, 123.5, 115.3, 114.4, 102.9, 36.9, 32.7, 22.2, 13.1; HRMS (ESI) m/z calcd for $\text{C}_{21}\text{H}_{18}\text{ClNNaO}_2$ $[\text{M} + \text{Na}]^+$: 374.0918, found 374.0922.

2-(2-Chlorobenzyl)-5-ethyl-8-methoxyfuro[2,3-*c*]quinolin-4(5H)-one (3h). Colorless solid (77.1 mg, 70%), mp 112.7–113.4 °C; IR (film) 3 2972, 1663, 1460, 1245 1, 958 cm^{-1} ; ^1H NMR (400 MHz,

CDCl₃) δ 7.44 (dd, J = 5.8, 3.5 Hz, 1H), 7.41–7.35 (m, 2H), 7.29–7.25 (m, 2H), 7.24–7.18 (m, 1H), 7.13 (dd, J = 9.2, 2.9 Hz, 1H), 6.58 (s, 1H), 4.46 (q, J = 7.1 Hz, 2H), 4.33 (s, 2H), 3.89 (s, 3H), 1.39 (t, J = 7.1 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 159.9, 154.8, 152.7, 142.1, 134.4, 134.2, 131.3, 131.2, 130.2, 129.8, 128.7, 127.2, 117.6, 116.9, 116.4, 107.1, 102.9, 55.7, 37.2, 32.7, 13.2; HRMS (ESI) m/z calcd for C₂₁H₁₈ClNNaO₃ [M + Na]⁺: 390.0867, found 390.0867.

5-Ethyl-2-(4-methylbenzyl)furo[2,3-c]quinolin-4(5H)-one (3i). Colorless oil (76.1 mg, 80%); IR (film) 2975, 1665, 1455, 1209, 957 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 7.76 (dd, J = 7.8, 1.2 Hz, 1H), 7.57–7.49 (m, 1H), 7.47 (d, J = 8.4 Hz, 1H), 7.31–7.27 (m, 1H), 7.24 (d, J = 8.1 Hz, 2H), 7.17 (d, J = 8.1 Hz, 2H), 6.59 (s, 1H), 4.49 (q, J = 7.1 Hz, 2H), 4.16 (s, 2H), 2.37 (s, 3H), 1.41 (t, J = 7.1 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 162.4, 153.3, 141.6, 136.8, 136.7, 133.4, 130.7, 129.5, 128.9, 128.6, 124.7, 122.1, 116.9, 115.1, 102.4, 37.0, 34.6, 21.1, 13.1; HRMS (ESI) m/z calcd for C₂₁H₁₉NNaO₂ [M + Na]⁺: 340.1308, found 340.1304.

5-Ethyl-8-methyl-2-(4-methylbenzyl)furo[2,3-c]quinolin-4(5H)-one (3j). Colorless oil (74.5 mg, 75%); IR (film) 2974, 1665, 1449, 1213, 959 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 7.53 (s, 1H), 7.35–7.28 (m, 2H), 7.21 (d, J = 8.0 Hz, 2H), 7.15 (d, J = 8.0 Hz, 2H), 6.53 (s, 1H), 4.44 (q, J = 7.1 Hz, 2H), 4.13 (s, 2H), 2.42 (s, 3H), 2.34 (s, 3H), 1.36 (t, J = 7.1 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 162.2, 153.1, 141.7, 136.6, 134.7, 133.4, 131.7, 130.4, 129.7, 129.4, 128.9, 124.6, 116.8, 114.9, 102.4, 36.9, 34.7, 21.1, 20.6, 13.2; HRMS (ESI) m/z calcd for C₂₂H₂₁NNaO₂ [M + Na]⁺: 354.1464, found 354.1466.

5-Ethyl-8-methoxy-2-(4-methylbenzyl)furo[2,3-c]quinolin-4(5H)-one (3k). Colorless oil (72.9 mg, 70%); IR (film) 2972, 1664, 1459, 1244, 958 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 7.33 (d, J = 9.2 Hz, 1H), 7.21 (d, J = 8.0 Hz, 2H), 7.17–7.12 (m, 3H), 7.11–7.07 (m, 1H), 6.51 (s, 1H), 4.42 (q, J = 7.1 Hz, 2H), 4.12 (s, 2H), 3.85 (s, 3H), 2.33 (s, 3H), 1.35 (t, J = 7.1 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 162.1, 154.8, 152.7, 141.9, 136.6, 133.4, 131.1, 130.2, 129.4, 128.9, 117.7, 116.8, 116.4, 107.0, 102.3, 55.7, 37.1, 34.6, 21.1, 13.2; HRMS (ESI) m/z calcd for C₂₂H₂₁NNaO₃ [M + Na]⁺: 370.1414, found 370.1417.

5-Ethyl-7-methyl-2-(4-methylbenzyl)furo[2,3-c]quinolin-4(5H)-one (3l). Yellow solid (77.5 mg, 78%), mp 90.2–90.3 °C; IR (film) 2975, 1665, 1450, 1257, 956 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 7.62 (d, J = 7.9 Hz, 1H), 7.25–7.18 (m, 3H), 7.15 (d, J = 8.0 Hz, 2H), 7.08 (d, J = 7.9 Hz, 1H), 6.52 (s, 1H), 4.45 (q, J = 7.1 Hz, 2H), 4.13 (s, 2H), 2.50 (s, 3H), 2.34 (s, 3H), 1.38 (t, J = 7.1 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 162.2, 153.3, 141.2, 138.8, 136.9, 136.6, 133.5, 130.7, 129.4, 128.9, 124.5, 123.4, 115.3, 114.5, 102.3, 36.9, 34.6, 22.2, 21.1, 13.1; HRMS (ESI) m/z calcd for C₂₂H₂₁NNaO₂ [M + Na]⁺: 354.1464, found 354.1465.

5-Ethyl-8-fluoro-2-(4-methylbenzyl)furo[2,3-c]quinolin-4(5H)-one (3m). Colorless oil (81.4 mg, 81%); IR (film) 2977, 1669, 1428, 1209, 963 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 7.71 (dd, J = 8.7, 6.2 Hz, 1H), 7.23 (d, J = 8.0 Hz, 2H), 7.20–7.11 (m, 3H), 7.04–6.97 (m, 1H), 6.54 (s, 1H), 4.42 (q, J = 7.1 Hz, 2H), 4.15 (s, 2H), 2.37 (s, 3H), 1.40 (t, J = 7.1 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 163.1 (d, J_{C-F} = 247.2 Hz), 162.7, 153.2, 140.8, 138.3 (d, J_{C-F} = 10.6 Hz), 136.7, 133.2, 130.4, 129.5, 128.9, 126.3 (d, J_{C-F} = 10.1 Hz), 113.3, 110.2 (d, J_{C-F} = 23.1 Hz), 102.3, 102.0, 37.4, 34.6, 21.1, 12.9; HRMS (ESI) m/z calcd for C₂₁H₁₈FNNaO₂ [M + Na]⁺: 358.1214, found 358.1212.

5-Ethyl-8-methyl-2-(thiophen-2-ylmethyl)furo[2,3-c]quinolin-4(5H)-one (3n). Brown solid (79.5 mg, 82%), mp 103.1–103.2 °C; IR (film) 2940, 1662, 1269, 807 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 7.56 (s, 1H), 7.36–7.29 (m, 2H), 7.22 (dd, J = 5.0, 1.3 Hz, 1H), 7.03–6.96 (m, 2H), 6.69 (s, 1H), 4.45 (q, J = 7.1 Hz, 2H), 4.39 (s, 2H), 2.44 (s, 3H), 1.37 (t, J = 7.1 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 160.6, 153.1, 141.8, 138.1, 134.8, 131.8, 130.3, 129.8, 127.1, 126.6, 124.7, 124.6, 116.7, 115.0, 102.6, 37.0, 29.2, 20.7, 13.1; HRMS (ESI) m/z calcd for C₁₉H₁₇NNaO₂S [M + Na]⁺: 346.0872, found 346.0872.

5-Ethyl-2-methylfuro[2,3-c]quinolin-4(5H)-one (3o). Colorless oil (55.8 mg, 82%); IR (film) 2976, 1716, 1665, 1449, 1211 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 7.80 (dd, J = 7.8, 1.4 Hz, 1H), 7.55–7.50 (m, 1H), 7.46 (d, J = 8.3 Hz, 1H), 7.33–7.28 (m, 1H), 6.67 (s, 1H), 4.48 (q, J = 7.1 Hz, 2H), 2.54 (d, J = 0.6 Hz, 3H), 1.39 (t, J = 7.1 Hz,

3H); ¹³C NMR (100 MHz, CDCl₃) δ 159.3, 153.2, 141.4, 136.8, 130.8, 128.5, 124.7, 122.1, 116.9, 115.1, 102.0, 36.9, 14.2, 13.1; HRMS (ESI) m/z calcd for C₁₄H₁₃NNaO₂ [M + Na]⁺: 250.0838, found 250.0840.

2-Ethyl-5-methylfuro[2,3-c]quinolin-4(5H)-one (3q). Colorless oil (47.7 mg, 70%); IR (film) 2974, 1665, 1448, 1235, 932 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 7.78 (d, J = 7.8 Hz, 1H), 7.55–7.48 (m, 1H), 7.42 (d, J = 8.5 Hz, 1H), 7.35–7.20 (m, 1H), 6.66 (s, 1H), 3.80 (s, 3H), 2.88 (q, J = 7.6 Hz, 2H), 1.38 (t, J = 7.6 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 164.9, 153.7, 141.2, 137.9, 130.7, 128.5, 124.4, 122.3, 116.7, 115.2, 100.6, 29.3, 21.9, 11.9; HRMS (ESI) m/z calcd for C₁₄H₁₃NNaO₂ [M + Na]⁺: 250.0838, found 250.0840.

2,5-Diethylfuro[2,3-c]quinolin-4(5H)-one (3r). Colorless oil (54.2 mg, 75%); IR (film) 2976, 1665, 1449, 1211, 979 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 7.81 (d, J = 7.8 Hz, 1H), 7.55–7.48 (m, 1H), 7.45 (d, J = 8.5 Hz, 1H), 7.28 (dd, J = 9.5, 5.3 Hz, 1H), 6.67 (s, 1H), 4.48 (q, J = 7.1 Hz, 2H), 2.88 (q, J = 7.6 Hz, 2H), 1.39 (t, J = 7.1 Hz, 3H), 1.39 (t, J = 7.6 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 164.8, 153.3, 141.2, 136.8, 130.7, 128.5, 124.7, 122.1, 117.0, 115.1, 100.5, 36.9, 21.9, 13.1, 11.9; HRMS (ESI) m/z calcd for C₁₅H₁₅NO₂ [M + Na]⁺: 264.0995, found 264.0997.

2-Benzyl-5-butyl-5,6-dihydro-4H-benzo[e]furo[2,3-c]azepin-4-one (3t). Colorless oil (57.9 mg, 56%); IR (film) 2958, 1641, 1461, 1269, 1016 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 7.51 (d, J = 7.3 Hz, 1H), 7.43–7.38 (m, 1H), 7.38–7.32 (m, 6H), 7.31–7.26 (m, 1H), 6.35 (s, 1H), 4.27 (s, 2H), 4.13 (s, 2H), 3.62 (t, J = 7.4 Hz, 2H), 1.71–1.54 (m, 2H), 1.34–1.22 (m, 2H), 0.90 (t, J = 7.4 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 159.9, 158.6, 143.7, 136.8, 135.0, 131.3, 129.5, 129.1, 128.7, 128.5, 128.3, 127.9, 126.9, 126.7, 106.3, 52.2, 47.5, 34.8, 30.7, 19.9, 13.8; HRMS (ESI) m/z calcd for C₂₃H₂₃NNaO₂ [M + Na]⁺: 368.1621, found 368.1623.

■ ASSOCIATED CONTENT

Supporting Information

The Supporting Information is available free of charge on the ACS Publications website at DOI: 10.1021/acs.joc.6b01774.

Results of NOESY experiments on **2m** and copies of ¹H, ¹³C NMR and HRMS spectra of all the new compounds (PDF)

■ AUTHOR INFORMATION

Corresponding Author

*E-mail: blyin@scut.edu.cn.

Notes

The authors declare no competing financial interest.

■ ACKNOWLEDGMENTS

This work was supported by grants from the National Natural Science Foundation of China (nos. 21272078 and 21572068) and from the Science and Technology Planning Project of Guangdong Province, China (no. 2014A020221035).

■ REFERENCES

- (1) (a) Nicolaou, K. C.; Hale, C. R. H.; Nilewski, C.; Ioannidou, H. A. *Chem. Soc. Rev.* **2012**, *41*, 5185. (b) Lu, R.-J.; Tucker, J. A.; Pickens, J.; Ma, Y.-A.; Zinevitch, T.; Kirichenko, O.; Konoplev, V.; Kuznetsova, S.; Sviridov, S.; Brahmachary, E.; Khasanov, A.; Mikel, C.; Yang, Y.; Liu, C.; Wang, J.; Freel, S.; Fisher, S.; Sullivan, A.; Zhou, J.; Stanfield-Oakley, S.; Baker, B.; Sailstad, J.; Greenberg, M.; Bolognesi, D.; Bray, B.; Koszalka, B.; Jeffs, P.; Jeffries, C.; Chucholowski, A.; Sexton, C. J. *Med. Chem.* **2009**, *52*, 4481. (c) Hughes, R. A.; Moody, C. J. *Angew. Chem., Int. Ed.* **2007**, *46*, 7930.
- (2) (a) Kumar, N. S.; Clement, J. A.; Mohanakrishnan, A. K. *Tetrahedron* **2009**, *65*, 822. (b) Segawa, Y.; Maekawa, T.; Itami, K. *Angew. Chem., Int. Ed.* **2015**, *54*, 66.

(3) For reviews of direct arylation of five-membered heteroaromatic rings, see: (a) Hassan, J.; Sévignon, M.; Gozzi, C.; Schulz, E.; Lemaire, M. *Chem. Rev.* **2002**, *102*, 1359. (b) Seregin, I. V.; Gevorgyan, V. *Chem. Soc. Rev.* **2007**, *36*, 1173. (c) Satoh, T.; Miura, M. *Chem. Lett.* **2007**, *36*, 200. (d) Bellina, F.; Rossi, R. *Tetrahedron* **2009**, *65*, 10269. (e) Roger, J.; Gottumukkala, A. L.; Doucet, H. *ChemCatChem* **2010**, *2*, 20. (f) Yamaguchi, J.; Yamaguchi, A. D.; Itami, K. *Angew. Chem., Int. Ed.* **2012**, *51*, 8960. (g) Rossi, R.; Bellina, F.; Lessi, M.; Manzini, C. *Adv. Synth. Catal.* **2014**, *356*, 17.

(4) For selected examples, see: (a) Park, C.-H.; Ryabova, V.; Seregin, I. V.; Sromek, A. W.; Gevorgyan, V. *Org. Lett.* **2004**, *6*, 1159. (b) Lane, B. S.; Brown, M. A.; Sames, D. J. *Am. Chem. Soc.* **2005**, *127*, 8050. (c) Martins, A.; Alberico, D.; Lautens, M. *Org. Lett.* **2006**, *8*, 4827. (d) Saha, D.; Adak, L.; Ranu, B. C. *Tetrahedron Lett.* **2010**, *51*, 5624. (e) Cao, H.; Shen, D.; Zhan, H.; Yang, L. *Synlett* **2011**, *2011*, 1472. (f) Cao, H.; Lin, Y.; Zhan, H.; Du, Z.; Lin, X.; Liang, Q.-M.; Zhang, H. *RSC Adv.* **2012**, *2*, 5972.

(5) (a) Glover, B.; Harvey, K. A.; Liu, B.; Sharp, M. J.; Tymoschenko, M. F. *Org. Lett.* **2003**, *5*, 301. (b) Chabert, J. F. D.; Joucla, L.; David, E.; Lemaire, M. *Tetrahedron* **2004**, *60*, 3221. (c) Colletto, C.; Islam, S.; Juliá-Hernández, F.; Larrosa, I. *J. Am. Chem. Soc.* **2016**, *138*, 1677.

(6) (a) Gorelsky, S. I.; Lapointe, B.; Fagnou, K. J. *Am. Chem. Soc.* **2008**, *130*, 10848. (b) Liégault, B.; Lapointe, D.; Caron, L.; Vlassova, A.; Fagnou, K. J. *Org. Chem.* **2009**, *74*, 1826.

(7) (a) Gottumukkala, A. L.; Doucet, H. *Adv. Synth. Catal.* **2008**, *350*, 2183. (b) Itahara, T. *J. Org. Chem.* **1985**, *50*, 5272. (c) Joo, J. M.; Touré, B. B.; Sames, D. J. *Org. Chem.* **2010**, *75*, 4911. (d) Lane, B. S.; Brown, M. A.; Sames, D. J. *Am. Chem. Soc.* **2005**, *127*, 8050. (e) Goikhman, R.; Jacques, T. L.; Sames, D. J. *Am. Chem. Soc.* **2009**, *131*, 3042. (f) Beck, E. M.; Grimster, N. P.; Hatley, R.; Gaunt, M. J. *J. Am. Chem. Soc.* **2006**, *128*, 2528. (g) Phipps, R. J.; Grimster, N. P.; Gaunt, M. J. *J. Am. Chem. Soc.* **2008**, *130*, 8172. (h) Daniels, M. H.; Armand, J. R.; Tan, K. L. *Org. Lett.* **2016**, *18*, 3310. (i) Yanagisawa, S.; Ueda, K.; Sekizawa, H.; Itami, K. *J. Am. Chem. Soc.* **2009**, *131*, 14622. (j) Tang, D.-T. D.; Collins, K. D.; Glorius, F. *J. Am. Chem. Soc.* **2013**, *135*, 7450. (k) Ueda, K.; Amaike, K.; Maceiczuk, R. M.; Itami, K.; Yamaguchi, J. *J. Am. Chem. Soc.* **2014**, *136*, 13226. (l) Maki, Y.; Goto, T.; Tsukada, N. *ChemCatChem* **2016**, *8*, 699 and ref 5c.

(8) (a) Lipshutz, B. H. *Chem. Rev.* **1986**, *86*, 795. (b) Bur, S. K.; Padwa, A. *Chem. Rev.* **2004**, *104*, 2401. (c) Lichtenthaler, F. W. *Acc. Chem. Res.* **2002**, *35*, 728. (d) Rosatella, A. A.; Simeonov, S. P.; Frade, R. F. M.; Afonso, C. A. M. *Green Chem.* **2011**, *13*, 754. (e) Gallezot, P. *Chem. Soc. Rev.* **2012**, *41*, 1538. (f) van Putten, R. J.; van der Waal, J. C.; de Jong, E.; Rasrendra, C. B.; Heeres, H. J.; de Vries, J. G. *Chem. Rev.* **2013**, *113*, 1499. (g) Trushkov, I. V.; Uchuskin, M. G.; Butin, A. V. *Eur. J. Org. Chem.* **2015**, *2015*, 2999.

(9) For selected recent examples, see: (a) Roger, J.; Požgan, F.; Doucet, H. *Adv. Synth. Catal.* **2010**, *352*, 696. (b) Roy, D.; Mom, S.; Beaupérin, M.; Henri Doucet, H.; Hierso, J.-C. *Angew. Chem., Int. Ed.* **2010**, *49*, 6650. (c) Fu, H. Y.; Doucet, H. *Eur. J. Org. Chem.* **2011**, *2011*, 7163. (d) Yan, T.; Chen, L.; Bruneau, C.; Dixneuf, P. H.; Doucet, H. *J. Org. Chem.* **2013**, *78*, 4177. (e) Juwaini, N. A. B.; Ng, J. K. P.; Seayad, J. *ACS Catal.* **2012**, *2*, 1787. (f) Li, Y.; Wang, J.; Huang, M.; Wang, Z.; Wu, Y.; Wu, Y. *J. Org. Chem.* **2014**, *79*, 2890. (g) Matsidik, R.; Martin, J.; Schmidt, S.; Obermayer, J.; Lombeck, F.; Nübling, F.; Komber, H.; Fazzi, D.; Sommer, M. *J. Org. Chem.* **2015**, *80*, 980.

(10) (a) Li, P.; Chai, Z.; Zhao, G.; Zhu, S.-Z. *Tetrahedron* **2009**, *65*, 1673. (b) Ionita, M.; Roger, J.; Doucet, H. *ChemSusChem* **2010**, *3*, 367. (c) Roy, D.; Mom, S.; Roger, S.; Lucas, D.; Hierso, J.-C.; Doucet, H. *ACS Catal.* **2012**, *2*, 1033. (d) Carrère, A.; Brinet, D.; Florent, J.-C.; Rousselle, P.; Bertounesque, E. *J. Org. Chem.* **2012**, *77*, 1316.

(11) (a) Larbi, K. S.; Fu, H. Y.; Laidou, N.; Beydoun, K.; Miloudi, A.; Abed, D. E.; Djabbar, S.; Doucet, H. *ChemCatChem* **2012**, *4*, 815. (b) Padmavathi, R.; Sankar, R.; Gopalakrishnan, B.; Parella, R.; Babu, S. A. *Eur. J. Org. Chem.* **2015**, *2015*, 3727.

(12) (a) Kaim, L. E.; Grimaud, L.; Wagschal, S. *Chem. Commun.* **2011**, *47*, 1887. (b) Yin, B.; Cai, C.; Zeng, G.; Zhang, R.; Li, X.; Jiang,

H. *Org. Lett.* **2012**, *14*, 1098. (c) Ji, F.; Yi, W.; Sun, M.; Lv, M.; Cai, C. *Mol. Diversity* **2013**, *17*, 295.

(13) (a) Beccalli, E. M.; Brogini, G.; Martinelli, M.; Paladino, G.; Zoni, C. *Eur. J. Org. Chem.* **2005**, *2005*, 2091. (b) Campeau, L. C.; Parisien, M.; Jean, A.; Fagnou, K. J. *Am. Chem. Soc.* **2006**, *128*, 581. (c) Ohno, H.; Iuchi, M.; Kojima, N.; Yoshimitsu, T.; Fujii, N.; Tanaka, T. *Chem. - Eur. J.* **2012**, *18*, 5352. (d) Tang, F.; Chen, C.; Zhou, Y.; Lin, C.; Zhang, J. *RSC Adv.* **2014**, *4*, 51298. (e) Abe, H.; Kamimura, M.; Komatsu, Y.; Horino, Y. *Heterocycles* **2015**, *90*, 1332.

(14) (a) Yin, B.-L.; Lai, J.-Q.; Zhang, Z.-R.; Jiang, H.-F. *Adv. Synth. Catal.* **2011**, *353*, 1961. (b) Yin, B.; Zeng, G.; Cai, C.; Ji, F.; Huang, L.; Li, Z.; Jiang, H. *Org. Lett.* **2012**, *14*, 616. (c) Yin, B.; Huang, L.; Wang, X.; Liu, J.; Jiang, H. *Adv. Synth. Catal.* **2013**, *355*, 370. (d) Yin, B.; Zhang, X.; Liu, J.; Li, X.; Jiang, H. *Chem. Commun.* **2014**, *50*, 8113. (e) Yin, B.; Zhang, X.; Zhang, X.; Peng, H.; Zhou, W.; Liu, B.; Jiang, H. *Chem. Commun.* **2015**, *51*, 6126. (f) Liu, J.; Zhang, X.; Peng, H.; Jiang, H.; Yin, B. *Adv. Synth. Catal.* **2015**, *357*, 727. (g) Ji, F.; Peng, H.; Zhang, X.; Lu, W.; Liu, S.; Jiang, H.; Liu, B.; Yin, B. *J. Org. Chem.* **2015**, *80*, 2092. (h) Peng, H.; Li, J.; Wang, F.; Liu, B.; Yin, B. *J. Org. Chem.* **2016**, *81*, 4939. (i) Li, J.; Peng, H.; Wang, F.; Wang, X.; Jiang, H.; Yin, B. *Org. Lett.* **2016**, *18*, 3226. (j) Zhang, X.; Liu, J.; Yang, Y.; Wang, F.; Jiang, H.; Yin, B. *Org. Chem. Front.* **2016**, *3*, 1105.

(15) For reviews of the bioactivities and syntheses of spirooxindoles, see: (a) Santos, M. M. M. *Tetrahedron* **2014**, *70*, 9735. (b) Marti, C.; Carreira, E. M. *Eur. J. Org. Chem.* **2003**, *2003*, 2209. (c) Williams, R. M.; Cox, R. J. *Acc. Chem. Res.* **2003**, *36*, 127. (d) Lin, H.; Danishefsky, S. J. *Angew. Chem., Int. Ed.* **2003**, *42*, 36. (e) Galliford, C. V.; Scheidt, K. A. *Angew. Chem., Int. Ed.* **2007**, *46*, 8748. (f) Trost, B. M.; Brennan, M. K. *Synthesis* **2009**, *2009*, 3003.

(16) (a) Lee, Y. R.; Kim, B. S.; Kweon, H. I. *Tetrahedron* **2000**, *56*, 3867. (b) Grundon, M. F. *Nat. Prod. Rep.* **1990**, *7*, 131.

(17) For a related example from our group, see: Liu, J.; Xu, X.; Li, J.; Liu, B.; Jiang, H.; Yin, B. *Chem. Commun.* **2016**, *52*, 9550.

(18) For a related example, see: Zhang, J.; Sha, S. C.; Bellomo, A.; Trongsiwat, N.; Gao, F.; Tomson, N. C.; Walsh, P. J. *J. Am. Chem. Soc.* **2016**, *138*, 4260.

(19) Lafrance, M.; Fagnou, K. J. *Am. Chem. Soc.* **2006**, *128*, 16496 and ref 6.